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Preamble
The goal of the research described in this thesis was to develop a portable diagnostic test
for the use at the-point-of-care.
This work was supervised by Prof. Dr. G. Winter from the Department of Pharmacy,
Pharmaceutical Technology & Biopharmaceutics of the LMU Munich, yet conducted at
the German Cancer Research Center in the group of Dr. Jörg Hoheisel - Division of Func-
tional Genome Analysis.
Identification of biomarkers and development of diagnostic measurement tools is the pre-
requisite to realize diagnostic concepts. With appropriate technology, it is possible to
determine whether a treatment can be started, how much drug has to be administered
and if a loss of therapy effectiveness occurs over time. In order to engage patients into
the process of disease monitoring, technologies, which can be used with a connected device
such as a smartphone from where the generated data can be shared, might become an
additional key component of an effective treatment.
The current work applies pharmaceutical technology expertise to design optimized protein-
based diagnostic assays with improved usability and make them applicable to established
detection systems, which can be widely used with portable medical devices. Adequacy of
the systems for therapeutic drug monitoring of biologicals was demonstrated in clinical
studies.
xi

1 Antibody characterization using
protein microarrays
1.1 Utilisation of antibody microarrays for the selection of
specific and informative antibodies from recombinant
library binders of unknown quality
The present chapter was published in the journal New biotechnology in September 2016:
Janek Kibat, Thomas Schirrmann, Matthias J Knape*, Saskia Helmsing, Doris Meier,
Michael Hust*, Christoph Schröder, Daniela Bertinetti, Gerhard Winter, Khalid Pardes,
Mia Funk, Andrea Vala, Nathalia Giese, Friedrich W. Herberg, Stefan Dübel, Jörg Hoheisel‡.
Utilisation of antibody microarrays for the selection of specific and informative antibodies
from recombinant library binders of unknown quality. New biotechnology, 33(5):574?581,
2016.
* These authors contributed equally to this work
‡ Corresponding author
As part of the Affinomics consortium this project was financially supported by the Euro-
pean Commission (EU grant contract no. 241481) with the intention to generate a variety
of binder molecules against a multitude of tumor-associated antigens (TAA), which could
be of therapeutic and/or diagnostic interest. In this regard, the overall strategy was divided
into four steps: 1. Selection of TAA, 2. Preparation of recombinant TAA and scale-up of
antigen production 3. Preparation of different binder formats against the produced TAA
4. Quality control of the manufactured binders.
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Without the help of our cooperation partners in Copenhagen1 (supply with antigens) and
Braunschweig2(supply with antibodies), Kassel3 (surface plasmon resonance experiments)
and Heidelberg4 (clinical samples) this work would not have been possible.
All microarray-related and immunohistochemistry experiments as well as the writing of
the manuscript was done by Janek Kibat.
The aim of this work was to describe a quick and convenient way which combines both,
the identification of potentially interesting drugable or diagnostic antigen targets as well as
the quality characterization of the used antibodies. Other than for small molecules and the
corresponding Lipinski’s rule of five, a preselection of potentially good or bad candidates
is difficult for macromolecules such as antibodies. Therefore, standardized characteriza-
tion methods and criteria, which determine the suitability of a therapeutic or diagnostic
antibody are needed.
1.1.1 Abstract
Many diagnostic and therapeutic concepts require antibodies of high specificity. Recom-
binant binder libraries and related selection approaches allow the efficient isolation of
antibodies against almost every target of interest. Nevertheless, it cannot be guaranteed
that selected antibodies perform well and interact specifically enough with analytes unless
an elaborate characterisation is performed. Here, we present an approach to shorten this
process by combining the selection of suitable antibodies with the identification of infor-
mative target molecules by means of antibody microarrays, thereby reducing the effort of
antibody characterisation by concentrating on relevant molecules. In a pilot scheme, a li-
brary of 456 single-chain variable fragment (scFv) binders to 134 antigens was used. They
were arranged in a microarray format and incubated with the protein content of clinical
tissue samples isolated from pancreatic ductal adenocarcinoma and healthy pancreas, as
well as recurrent and non-recurrent bladder tumours. We observed significant variation in
the expression of the E3 ubiquitin-protein ligase (CHFR) as well as the glutamate recep-
tor interacting protein 2 (GRIP2), for example, always with more than one of the scFvs
binding to these targets. Only the relevant antibodies were then characterised further
on antigen microarrays and by surface plasmon resonance experiments so as to select the
1Khalid Pardes, Mia Funk, Andrea Vala
2Thomas Schirrmann, Saskia Helmsing, Doris Meier, Michael Hust, Stefan Dübel
3Matthias J. Knape, Daniela Bertinetti, Friedrich W. Herberg
4Nathalia Giese
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most specific and highest affinity antibodies. These binders were in turn used to confirm
a microarray result by immunohistochemistry analysis.
1.1.2 Introduction
The demand for highly specific and high-affinity antibodies is continuously and rapidly
growing [1]. The advances in genomic sequencing, for example, are uncovering more and
more disease-related changes, which frequently need to be elucidated in protein-based as-
says since they exhibit their functional effect at this molecular level. Companion diag-
nostics, in which the application of a drug is directly coupled to a patient stratification
process, is also of increasing importance. Since most drugs affect proteins, most assays
will probably analyse this molecular class, too. Access to antibodies is crucial for such
ends. Currently, the antibody field is still dominated by monoclonal antibodies isolated
from hybridoma cells [2]. While they represent the gold standard at present, binders that
originate from recombinant selection systems are catching up quickly and are expected to
become the norm sooner rather than later [3] and [4]. Based on libraries that can match
the antibody diversity of the human immune system, they allow the isolation of binders
to almost any desired target. They also permit flexibility with respect to the actual ap-
plication profile. Binders against linear epitopes, for example, may not be suitable for
recognition of three-dimensional structures and vice versa. By adaptation of the selection
parameters, antibodies from a single library can meet varying requirements. However,
similar to antibodies from hybridomas, the production of recombinant binders faces the
common problem that individual molecules resulting from the initial selection screens differ
tremendously in quality, in particular with respect to specificity and affinity. The majority
of generated molecules will eventually fail quality requirements at some stage, making the
effort already invested on characterisation useless and void.
In an effort to shorten the usually successively executed processes of antibody production,
characterisation, application for antigen identification and selection of binders that exhibit
appropriate performance parameters and are of informative value, we propose to combine
the last three steps, at least partially, by means of binder microarrays. After an initial
selection process - panning from a library by removing the antibodies that do not bind
the targeted antigens at all - the remaining antibodies will be arrayed and incubated with
protein samples of interest. For lack of any extensive characterisation, a large percentage
of the primary antibody hits will be identified immediately as being of inadequate quality.
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At the same time, however, molecules will be found that exhibit at least some degree of
specificity and yield reproducible results that could be of biological or biomedical rele-
vance. Only antibodies that meet sufficiently both requirements - binding specificity and
informative value - will be characterised further in order to determine their quality. Once
quality is established, the antibodies can then be used to confirm in other analysis formats
the biological finding made in the microarray experiment.
In a pilot experiment, we have investigated a set of 456 recombinant antibodies. They
were made within the framework of the Affinomics consortium, the most recent of three
European networks for binder production and characterisation [5], and were designed to
bind 134 tumour-associated antigens. Instead of selecting the best candidates in a one-
by-one analysis of specificity and affinity, they were arranged as an antibody microarray
without knowing about their quality. By incubation with clinical protein samples, we could
combine the identification of proteins, which exhibit differential expression, with an identi-
fication of related antibodies with apparently appropriate performance. These antibodies
were then subjected to further characterisation. Molecules that passed the process were
subsequently used to validate the original microarray result by immunohistochemistry.
In the analysis, protein extracts from pancreatic and bladder cancer were used as well as
appropriate controls. Pancreatic cancer is currently the most lethal cancer entity in the
Western world [6]. Most patients die within a year of diagnosis, with mean survival being
about five months; mortality is basically identical to incidence. In comparison, bladder
cancer is far less lethal and frequently diagnosed relatively early. Low-stage, non muscle-
invasive bladder cancer can usually be resected successfully. However, 60% of the tumours
recur and then often become invasive [7].
1.1.3 Materials and Methods
1.1.3.1 Antibody microarray production
The antibodies were part of the human single-chain variable fragment (scFv) gene libraries
HAL4/7/8 [8] and HAL9/10 [9]. Initial selections against 134 antigens (132 proteins and 2
peptides; Supplementary Tab. 1) of oncological context and poor coverage by commercial
monoclonal antibodies were performed by library panning as described [10] leading to a
set of 456 scFvs. Concentration dependent binding to the respective target molecules
was confirmed by an ELISA using dilution series of the antibodies. The scFvs were then
re-cloned so as to link them to a human IgG1 Fc part as described in detail [8]. The
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fusion proteins have superior stability. Experimentally, they behave very similarly to IgG
antibodies and can be used with them in immunoassays without changing the underlying
protocols. The antibodies were expressed in HEK293 6E cells and purified by affinity
chromatography on protein A [11]. Antibody microarrays were prepared as described in
detail previously [12]and [13]. In brief, the antibodies were spotted onto epoxysilane-
coated slides (25 mm x 75 mm, Nexterion-E; Schott, Jena, Germany) using the contact
printer MicroGrid II 610 (Apogent Discoveries, Mittenwald, Germany) and SMP6B pins
(Telechem, Sunnyvale, USA) at a humidity of 55 - 65%. The printing buffer was composed
of 50 mM sodium bicarbonate, pH 9.0, 100 mM NaCl, 50 mM MgCl2, 0.005% (w/v) sodium
azide, 0.25% (w/v) dextran, 0.006% (w/v) Igepal CA-630 (Sigma-Aldrich, St. Louis, USA)
and 1 mg/ml of the respective antibody. All antibodies were spotted in quadruplicate on
each microarray slide. The spots featured a diameter of about 250 µm. After the actual
printing process, the slides were allowed to equilibrate at room temperature and 55-65%
humidity overnight. They were then stored in dry and dark conditions at 4◦C.
1.1.3.2 Preparation of protein samples
For all tissue samples, written informed consent was obtained from the patients or donors.
The analyses performed were approved by the local ethics committee. As a matter of
fact, tumour specimens were used, which had been studied before in a different setting.
The bladder cancer samples had been isolated from patients with and without tumour
recurrence after five years [14]. Also, we used nine tissue samples of patients with pancre-
atic adenocarcinoma (PDAC) and seven pancreas samples of patients, who had no cancer
but had their pancreas removed for other reasons [15; unpublished results]. The protein
extracts had been prepared as described in detail previously [13]. Total protein concen-
tration was measured by the BCA assay (Thermo Fisher Scientific, Waltham, USA) and
adjusted to 1 mg/ml. The protein was labelled with 0.4 mg/ml of the NHS-ester of the
fluorescent dye Dy-549 (Dyomics, Jena, Germany) in 100 mM sodium bicarbonate buffer,
pH 8.5, 1% (w/v) Triton-100 on a shaker at 4◦C. After 1 h, the reaction was stopped
by addition of 10% glycine. Unreacted dye was removed 30 min later and the buffer
changed to phosphate-buffered saline (PBS) using Zeba Desalt columns (Thermo Fisher
Scientific). While stoichiometric labelling is possible [15], it is not used routinely. Varia-
tions in labelling efficiency are normalised during the data analysis process. Subsequently,
the Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany) was added as
recommended by the manufacturer. All labelled protein samples were stored in aliquots at
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−20◦C until use. For competitive dual-colour incubation [16], a common reference sample
was produced by pooling identical amounts of all protein samples and labelling the pool
with the dye Dy-649 (Dyomics). The same reference sample was used throughout the
analyses.
1.1.3.3 Antibody microarray analysis
Surface blocking and sample incubation were performed using a Tecan HS 4800 hybridisa-
tion system (Tecan, Männedorf, Switzerland). Slides were blocked with the Candor Block-
ing Solution (Candor Biosciences, Wangen, Germany) for 1 h and incubated with labelled
protein for 3 h. Subsequently, the slides were scanned with a Tecan Powerscanner and
images were analysed using GenePix 6.0 microarray analysis software (Axon Instruments,
Union City, USA). Chipster software version 3.3 (http://chipster.csc.fi/) was applied for
loess normalisation and statistical analysis.
1.1.3.4 Antigen microarray analysis
Full-length antigens were produced at the Københavns Universitet NNF Center for Pro-
tein Research (UCPH) by expression in E. coli and purified via a polyhistidine tag. To
assure their purity, all proteins were tested by SDS-PAGE prior to immobilisation. The
list of the 54 antigens used in the analysis is shown in Supplementary Tab. 2. The antigen
microarrays were prepared as described for the antibody microarrays. For spotting, how-
ever, a glycerol-based buffer (0.4 M NaHPO4, pH 8.6, 10% glycerol, 0.01% (w/v) sarkosyl)
was used. Each antigen was spotted in triplicate within each of eight identical sub-arrays
placed on one microarray slide. Incubation with antibodies was performed within 24 h after
spotting. After an initial blocking with the Candor Blocking Solution, 250 µl 33 nM recom-
binant antibody was incubated on the arrays for 1 h. After washing, DY-649-P1-labelled
protein A/G (Biotrend, Cologne, Germany) was added for detection to a concentration of
20 nM and incubated for 30 min. Experiments were carried out in triplicate.
1.1.3.5 Affinity measurements by surface plasmon resonance (SPR)
A Sierra Sensors SPR-4 instrument (Sierra Sensors, Hamburg, Germany) was used to
acquire binding kinetics of selected scFv-Fc:antigen pairs. Antigens were immobilised
covalently to a flat amine sensor chip to a level of 350 RU (protein CHFR) or 300 RU
(GRIP2). Interaction analysis was performed by injecting several concentrations of the
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corresponding scFv-Fc antibody diluted in PBS buffer at a flow rate of 30 µl/min. After
each injection the surface was regenerated using 10 mM glycine (pH 1.9) for 30 s. All
measurements were performed at 25◦C. Non-specific binding, monitored on a blank flow
cell, was subtracted from the SPR signals. Rate constants were determined using the
SPR-4 analysis software (Sierra Sensors) assuming a 1:1 Langmuir binding model.
1.1.3.6 Immunohistochemistry (IHC)
For immunohistochemistry experiments, frozen tissue sections were produced. They were
fixed with −20◦C cold acetone for 5 min. Peroxidases were quenched with a 3% (v/v) H2O2
solution in methanol. Slides and tissue sections were first blocked with avidin (Dako, Kyoto,
Japan) for 10 min, second with biotin (Dako) for 10 min and finally with Power Block
(BioGenex, San Ramon, USA) for 1 h. Recombinant antibodies were biotinylated with
EZ-Link NHS-PEG4-Biotin according to the manufacturer’s protocol, diluted in antibody
diluent (Dako S3022) to a concentration of 5-10 µg/ml and incubated on the sections
overnight at 4◦C. Prior to the incubation with streptavidin peroxidase (Kirkegaard &
Perry Laboratories) for 30 min, slides were washed with Tris-buffer supplemented with
0.05% Tween-20. The colour reaction was carried out by incubation for 2 min with liquid
DAB+ substrate (Dako) and counterstaining by Mayer’s hematoxylin solution (Merck,
Darmstadt, Germany). Images were captured using a Zeiss Cell Observer Z1 equipped
with an AxioCam (Zeiss, Jena, Germany).
1.1.4 Results
1.1.4.1 Comparative antibody microarray analysis
The binder set used in this pilot study consisted of phage display selected single chain
variable fragments (scFvs) isolated from universal phage display libraries, which allow the
high-throughput selection of human antibody fragments. After initial selection by panning
against 134 proteins or peptides (Supplementary Tab. 1), a set of 456 scFvs was picked
from the binding molecules. Each scFv was fused to a human Fc-fragment in order to
create scFv-Fc fusion antibodies. This binder format can be used equivalent to human
IgGs [17] and [18]. In order to investigate which of the constructs should be studied in
more detail, the scFv-Fc antibodies were spotted onto microarrays and incubated with
clinical samples (Fig. 1.1 a). Incubation was with fluorescently labelled protein lysates
obtained from pancreatic adenocarcinoma (PDAC) and healthy pancreas tissues as well
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as resected bladder tumours from patients, who subsequently had either suffered tumour
recurrence within five years of tumour resection or had no relapse. All samples had been
studied before [14] and were known to exhibit expression differences for proteins other than
those represented by the scFv-Fc fusion antibodies used here.
same target and that this target was differentially expressed in the
investigated sample cohorts. These antibodies (Table 1) were
selected for further characterisation.
Quality control of selected antibodies
After their initial isolation from the recombinant library, all scFv-
Fc antibodies had been used for ELISAs, testing if they recognized
the antigen by which they were selected in the panning process.
However, these tests only determined if an antibody was able to
bind its target, but did not provide any information about speci-
ficity. In order to investigate the degree of cross-reactivity of the
candidate antibodies selected by the microarray analysis, they
were incubated individually on an antigen array onto which
full-length proteins had been spotted (Fig. 1b–d). In our pilot
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FIGURE 1
Typical results of microarray analyses. (a) Overlay-image of the scFv-Fc antibody microarray incubated with protein samples from PDAC tissue (green signal) and
the common reference (red signal). Depending on the amount of protein binding to each spot in comparison to the common reference, colours vary from green,
via yellow and orange to red. (b)–(d) Images are shown of incubations on the antigen microarrays of antibodies DM380-JA70-F6 (b), DM319-JA37-E9 (c) and
DM319-JA37-B11 (d). Bound scFv-Fc antibody was detected with fluorescently labelled protein A/G. White spots indicate a signal that is too intense to be
presented in colour. Spot streaking is an experimental artefact introduced during drying the arrays with pressurised air.
FIGURE 2
Visualisation of the antibody microarray analysis results as volcano plots. (Left panel) Relative variation of protein abundance in lysates of normal pancreatic and
PDAC tissues, respectively. A negative log2 fold change indicates down-regulation, while a positive change indicates overexpression of proteins in PDAC tissue
compared to normal tissue. (Right panel) The same is shown for proteins in non-recurrent versus recurrent bladder cancer tissues. Dots of the same colour
represent antibodies which were meant to recognize the same antigen; the colour code is given. The names of some relevant antibodies are shown. The dotted
horizontal line represents a p-value of 0.05.
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Figure 1.1: Typical results of microarray analyses.
(a) Overlay-image of the scFv-Fc antibody microarray incubated with protein
samples from PDAC tissu (green signal) and the c mmon ref re e (red
signal). Depending on the amount of protein binding to each spot in
comparison to he comm n refe ence, colou s vary from green, via yellow and
orange to red. (b) - (d) Images are shown of incubations on the antigen
microarrays of antibodies DM380-JA70-F6 (b), DM319-JA37-E9 (c) and
DM319-JA37-B11 (d). Bound scFv-Fc antibody was detected with
fluorescently labelled protein A/G. White spots indicate a signal that is too
intense to be presented in colour. Spot streaking is an experimental artefact
introduced during drying the arrays with pressurised air.
Sample labelling and incubation as well as data analysis were performed according to
well-established procedures [12] and [16]. Volcano plots (Fig. 1.2) present the degree and
significance of differential protein expression. In total, antibodies to 31 proteins exhibited
a potentially significant up- or down-regulation in PDAC compared to normal tissues, and
antibodies to 38 proteins showed such changes when comparing non-recurrent and recur-
rent bladder cancer tissues. Since 9 proteins were shared by both analyses, an overall total
of 60 proteins was found to be potentially differentially ex essed in the initial analysis.
For the other 84 of the 134 proteins f r which antibodies had een isolated, no variation
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same target and that this target was differentially expressed in the
investigated sample cohorts. These antibodies (Table 1) were
selected for further characterisation.
Quality control of selected antibodies
After their initial isolation from the recombinant library, all scFv-
Fc antibodies had been used for ELISAs, testing if they recognized
the antigen by which they were selected in the panning process.
However, these tests only determined if an antibody was able to
bind its target, but did not provide any information about speci-
ficity. In order to investigate the degree of cross-reactivity of the
candidate antibodies selected by the microarray analysis, they
were incubated individually on an antigen array onto which
full-length proteins had been spotted (Fig. 1b–d). In our pilot
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the common reference (red signal). Depending on the amount of protein binding to each spot in comparison to the common reference, colours vary from green,
via yellow and orange to red. (b)–(d) Images are shown of incubations on the antigen microarrays of antibodies DM380-JA70-F6 (b), DM319-JA37-E9 (c) and
DM319-JA37-B11 (d). Bound scFv-Fc antibody was detected with fluorescently labelled protein A/G. White spots indicate a signal that is too intense to be
presented in colour. Spot streaking is an experimental artefact introduced during drying the arrays with pressurised air.
FIGURE 2
Visualisation of the antibody microarray analysis results as volcano plots. (Left panel) Relative variation of protein abundance in lysates of normal pancreatic and
PDAC tissues, respectively. A negative log2 fold change indicates down-regulation, while a positive change indicates overexpression of proteins in PDAC tissue
compared to normal tissue. (Right panel) The same is shown for proteins in non-recurrent versus recurrent bladder cancer tissues. Dots of the same colour
represent antibodies which were meant to recognize the same antigen; the colour code is given. The names of some relevant antibodies are shown. The dotted
horizontal line represents a p-value of 0.05.
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Figure 1.2: Visualisation of the antibody microarray analysis results as volcano plots.
(Left panel) Relative variation of protein abundance in lysates of normal
pancreatic and PDAC tissues, respectively. A negative log2 fold change
indicates down-regulation, while a positive change indicates overexpression of
pr teins in PDAC tissue compared to normal tissue. (Right panel) The same
is shown for proteins in non-recurrent versus recurrent bladder cancer tissues.
Dots of the same colour represent antibodies which were meant to recognize
the same antigen; the colour code is given. The names of some relevant
antibodies are shown. The dotted horizontal line represents a p-value of 0.05.
was identified. This could be due either to the lack of y such difference in the studied
protein samples or the absence of an antibody of sufficient sensitivity or specificity. For the
majority of the 60 proteins that yielded varying signals, there was only one antibody that
showed this variation, while the other binders that were intended to bind to the same tar-
get did not produce such a result. Four proteins - CHFR, ITCH, GORASP2 and GRIP2 -
exhibited significant variations on more than one of the antibodies that had been produced
against them (Fig. 1.2). The consistent results made it likely that the relevant scFv-Fc
antibodies actually bound to the same target and that this target was differentially ex-
pressed in the investigated sample cohorts. These antibodies (Table 1.1) were selected for
further characterisation.
1.1.4.2 Quality control of selected antibodies
After their initial isolation from the recombinant library, all scFv-Fc antibodies had been
used for ELISAs, testing if they recognized the antigen by which they were selected in the
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Table 1.1: List of antibodies selected for further characterisation.
’+’ indicates the detection of a variation in the abundance of the assumed
target protein upon incubation of the antibody microarray with protein
extracts isolated from clinical tissue samples.
scheme, 54 proteins were presented on the antigen array, includ-
ing CHFR, ITCH, GORASP2 and GRIP2 (Supplementary Tab. 2).
Only the anti-CHFR antibody DM319-JA37-G5 (Fig. 3a) and
the anti-GRIP2 antibodies DM380-JA70-F6 and -A8 (Fig. 4a) rec-
ognized their target proteins with good specificity. The other
candidates were either cross-reactive (anti-CHFR antibodies
DM319-JA37-A9, -B11 and-E9) or did not bind to the antigen array
at all (anti-GRIP2 antibody DM380-JA70-G4 as well as all anti-
ITCH and anti-GROASP2 antibodies). The cross-reactive anti-
CHRF antibodies produced very similar binding patterns, also
recognizing the proteins DPOLL, OSTP1, OTUB1 and PRDM8,
but with varying intensities (Fig. 3a). For confirmation that
ITCH and GROASP2 did not interact with their antibodies, the
proteins were labelled fluorescently and individually incubated on
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TABLE 1
List of antibodies selected for further characterisation. ‘+’ indicates the detection of a variation in the abundance of the assumed target
protein upon incubation of the antibody microarray with protein extracts isolated from clinical tissue samples.
Antibody name Antigen specificity (presumed) PDAC versus normal Bladder cancer recurrent versus non-recurrent
DM319-JA37-E9 CHFR
Uniprot ID: Q96EP1
+
DM319-JA37-G5 CHFR +
DM319-JA37-A9 CHFR +
DM319-JA37-B11 CHFR +
DM319-JA37-H7 CHFR +
DM319-JA37-D4 CHFR +
DM379-JA69-F11 GORASP2
Uniprot ID: Q9H8Y8
+
DM379-JA69-C9 GORASP2 +
DM379-JA69-G7 GORASP2 +
DM379-JA69-H3 GORASP2 +
DM379-JA69-E4 GORASP2 +
DM380-JA70-F6 GRIP2
Uniprot ID: Q9C0E4
+
DM380-JA70-A8 GRIP2 +
DM380-JA70-G4 GRIP2
DM380-JA70-B1 GRIP2 +
DM382-JA72-B7 ITCH
Uniprot ID: Q96J02
+ +
DM382-JA72-H1 ITCH
FIGURE 3
Quality control of anti-CHFR antibodies. (a) Binding intensities on the antigen arrays are shown. Signal intensities were normalised to the value achieved with an
immobilised control antibody. The desired target antigen is marked in red. For better visualisation, no error bars are shown. However, the data is available as
Supplementary Tab. 3. (b) SPR binding curves of two anti-CHFR scFv-Fc antibodies are shown. (c) SPR binding curves are presented of the best performing
antibody (DM319-JA37-G5) at different concentrations; from this, a KD of 82.2 nM was calculated.
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panning process. However, these tests only determined if an antibody was able to bind its
target, but did not provide any information about specificity. In order to investigate the
degree of cross-reactivity of the candidate antibodies selected by the microarray analysis,
they were incubated individually on an antigen array onto which full-length proteins had
been spotted (Fig. 1.1 b - d). In our pilot scheme, 54 proteins were presented on the antigen
array, including CHFR, ITCH, GORASP2 and GRIP2 (Supplementary Tab. 2). Only the
anti-CHFR antibody DM319-JA37-G5 (Fig. 1.3 a) and the anti-GRIP2 antibodies DM380-
JA70-F6 and -A8 (Fig. 1.4 a) recognized their target proteins with good specificity. The
other candidates were either cross-reactive (anti-CHFR antibodies DM319-JA37-A9, -B11
and-E9) or did not bind to the antigen array at all (anti-GRIP2 antibody DM380-JA70-G4
as well as all anti-ITCH and anti-GROASP2 antibodies). The cross-reactive anti-CHRF
antibodies produced very similar binding patterns, also recognizing the proteins DPOLL,
OSTP1, OTUB1 and PRDM8, but with varying intensities (Fig. 1.3 a). For confirma-
tion that ITCH and GROASP2 did not interact with their antibodies, the proteins were
labelled fluorescently and individually incubated on antibody microarrays. In this inverse
system too, there was no binding to the respective antibodies (data not shown), which was
surprising as they had exhibited binding in ELISA tests previously.
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scheme, 54 proteins were presented on the antigen array, includ-
ing CHFR, ITCH, GORASP2 and GRIP2 (Supplementary Tab. 2).
Only the anti-CHFR antibody DM319-JA37-G5 (Fig. 3a) and
the anti-GRIP2 antibodies DM380-JA70-F6 and -A8 (Fig. 4a) rec-
ognized their target proteins with good specificity. The other
candidates were either cross-reactive (anti-CHFR antibodies
DM319-JA37-A9, -B11 and-E9) or did not bind to the antigen array
at all (anti-GRIP2 antibody DM380-JA70-G4 as well as all anti-
ITCH and anti-GROASP2 antibodies). The cross-reactive anti-
CHRF antibodies produced very similar binding patterns, also
recognizing the proteins DPOLL, OSTP1, OTUB1 and PRDM8,
but with varying intensities (Fig. 3a). For confirmation that
ITCH and GROASP2 did not interact with their antibodies, the
proteins were labelled fluorescently and individually incubated on
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+
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DM380-JA70-F6 GRIP2
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+
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+ +
DM382-JA72-H1 ITCH
FIGURE 3
Quality control of anti-CHFR antibodies. (a) Binding intensities on the antigen arrays are shown. Signal intensities were normalised to the value achieved with an
immobilised control antibody. The desired target antigen is marked in red. For better visualisation, no error bars are shown. However, the data is available as
Supplementary Tab. 3. (b) SPR binding curves of two anti-CHFR scFv-Fc antibodies are shown. (c) SPR binding curves are presented of the best performing
antibody (DM319-JA37-G5) at different concentrations; from this, a KD of 82.2 nM was calculated.
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Figure 1.3: Quality control of anti-CHFR antibodies.
(a) Binding intensities on the antigen arrays are shown. Signal intensities were
normalised to the value achieved with an immobilised control antibody. The
desired target antigen is marked in red. For better visualisation, no error bars
are shown. However, the data is available as Supplementary Tab. 3. (b) SPR
binding curves of two anti-CHFR scFv-Fc antibodies are shown. (c) SPR
binding curves are presented of the best performing antibody
(DM319-JA37-G5) at different concentrations; from this, a KD of 82.2 nM was
calculated.
To qualify the array-based results further, the affinities of the anti-CHFR and anti-GRIP2
antibodies were measured quantitatively with SPR. For comparison to the antigen array
data, the antigens were immobilised and the antibodies were added in different concen-
trations. Anti-CHFR antibodies DM319-JA37-G5 (specific) and DM319-JA37-E9 (cross-
reactive) showed comparable binding kinetics with moderate dissociation rates (Fig. 1.3
b). Assuming a 1:1 Langmuir binding model, a KD of 82.2 nM could be calculated for anti-
CHFR antibody DM319-JA37-G5 (Fig. 1.3 c). For the anti-GRIP2 antibodies (Fig. 1.4),
there was strong binding of the specific binder DM380-JA70-F6, which was also charac-
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antibody microarrays. In this inverse system too, there was no
binding to the respective antibodies (data not shown), which was
surprising as they had exhibited binding in ELISA tests previously.
To qualify the array-based results further, the affinities of the
anti-CHFR and anti-GRIP2 antibodies were measured quantitative-
ly with SPR. For comparison to the antigen array data, the antigens
were immobilised and the antibodies were added in different
concentrations. Anti-CHFR antibodies DM319-JA37-G5 (specific)
and DM319-JA37-E9 (cross-reactive) showed comparable binding
kinetics with moderate dissociation rates (Fig. 3b). Assuming a 1:1
Langmuir binding model, a KD of 82.2 nM could be calculated for
anti-CHFR antibody DM319-JA37-G5 (Fig. 3c). For the anti-GRIP2
antibodies (Fig. 4), there was strong binding of the specific binder
DM380-JA70-F6, which was also characterised by its slow dissoci-
ation rate, whereas for the antibodies DM380-JA70-A8 (specific)
and DM380-JA70-G4 (cross-reacting) binding was significantly
weaker. A KD of 6.5 nM was calculated for DM380-JA70-F6.
Confirmation of GRIP2 overexpression by immunohistochemistry
Some of the antibodies that had yielded apparently interesting
data in the microarray analysis could be confirmed by the quality
control experiments as binders of good specificity and affinity. In
turn, we used one of these good performers for validating the
differential protein abundance in the tumour samples observed in
the microarray analysis. To this end, immunohistochemistry was
carried out on frozen tissue sections (Fig. 5). Besides confirming
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FIGURE 4
Quality control of anti-GRP2 antibodies. (a) Binding intensities on the antigen array are shown. Signal intensities were normalised to that of an immobilised control
antibody. The desired target antigen is marked in red. (b) SPR binding curves of three anti-GRIP2 scFv-Fc antibodies are shown. (c) SPR binding curves are
presented of the best performing antibody at different concentrations; from this, a KD of 6.5 nM was calculated.
FIGURE 5
Immunohistochemistry analysis of GRIP2 abundance in pancreatic tissues. Tissues isolated from patients with PDAC or chronic pancreatitis and from donors with
healthy pancreatic tissue (normal) were stained with two antibodies. The antibody DM380-JA70-F6 clearly showed a higher abundance of GRIP2 in diseased
pancreas.
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Figure 1.4: Quality control of anti-GRP2 antibodies.
(a) Binding intensities on the antigen array are shown. Signal intensities were
normalised to that of an immobilised control antibody. The desired target
antigen is marked in red. (b) SPR binding curves of three anti-GRIP2 scFv-Fc
antibodies are shown. (c) SPR binding curves are presented of the best
performing antibody at different concentrations; from this, a KD of 6.5 nM
was calculated.
terised by its slow dissociation rate, whereas for the antibodies DM380-JA70-A8 (specific)
and DM380-JA70-G4 (cross-reacting) binding was significantly weaker. A KD of 6.5 nM
was calculated for DM380-JA70-F6.
1.1.4.3 Confirmation of GRIP2 overexpression by immunohistochemistry
Some of the antibodies that had yielded apparently interesting data in the microarray anal-
ysis could be confirmed by the quality control experiments as binders of good specificity
and affinity. In turn, we used one of these good performers for validating the differential
protein abundance in the tumour samples observed in the microarray analysis. To this
end, immunohistochemistry was carried out on frozen tissue sections (Fig. 1.5). Besides
confirming the biological variation seen in the microarray assay, the immunohistochem-
istry assay allowed simultaneous testing of the binder performance. Analysing pancreatic
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tissue sections with the specific and high-affinity anti-GRIP2 antibody DM380-JA70-F6
confirmed that GRIP2 was highly abundant in PDAC and chronic pancreatitis compared
to normal tissue. As expected, antibody DM380-JA70-G4 produced inconclusive results.
antibody microarrays. In this inverse system too, there was no
binding to the respective antibodies (data not shown), which was
surprising as they had exhibited binding in ELISA tests previously.
To qualify the array-based results further, the affinities of the
anti-CHFR and anti-GRIP2 antibodies were measured quantitative-
ly with SPR. For comparison to the antigen array data, the antigens
were immobilised and the antibodies were added in different
concentrations. Anti-CHFR antibodies DM319-JA37-G5 (specific)
and DM319-JA37-E9 (cross-reactive) showed comparable binding
kinetics with moderate dissociation rates (Fig. 3b). Assuming a 1:1
Langmuir binding model, a KD of 82.2 nM could be calculated for
anti-CHFR antibody DM319-JA37-G5 (Fig. 3c). For the anti-GRIP2
antibodies (Fig. 4), there was strong binding of the specific in er
DM380-JA70-F6, which was also characterised by its slow dissoci-
ation rate, whereas for the antibodies DM380-JA70-A8 (specific)
and DM380-JA70-G4 (cross-reacting) binding was significantly
weaker. A KD of 6.5 nM was calculated for DM380-JA70-F6.
Confirmation of GRIP2 overexpression by immunohistochemistry
Some of the antibodies that had yielded apparently interesting
data in the microarray analysis could be confirmed by the quality
control experiments as binders of good specificity and affinity. In
turn, we used one of these good performers for validating the
differential protein abundance in the tumour samples observed in
he microarray analysis. To this end, immunohistochemistry was
carried out on frozen tissue ections (Fig. 5). Besides confirming
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antibody. The desired target antigen is marked in red. (b) SPR binding curves of three anti-GRIP2 scFv-Fc antibodies are shown. (c) SPR binding curves are
presented of the best performing antibody at different concentrations; from this, a KD of 6.5 nM was calculated.
FIGURE 5
Immunohistochemistry analysis of GRIP2 abundance in pancreatic tissues. Tissues isolated from patients with PDAC or chronic pancreatitis and from donors with
healthy pancreatic tissue (normal) were stained with two antibodies. The antibody DM380-JA70-F6 clearly showed a higher abundance of GRIP2 in diseased
pancreas.
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Figure 1.5: Immunohistochemistry analysis of GRIP2 abundance in pancreatic tissues.
Tissues isolated from patients with PDAC or chronic pancreatitis and from
donors with healthy pancreatic tissue (normal) were stained with two
antibodies. The antibody DM380-JA70-F6 clearly showed a higher abundance
of GRIP2 in diseased pancreas.
1.1.5 Discussion
Although only performed on a small-scale, these pilot experiments demonstrated the feasi-
bility of screening, by means of antibody microarrays, a preselected antibody library con-
taining binders of unknown quality for the isolation of useful antibodies, without testing
the performance parameters of every single candidate beforehand. Simultaneously, utilising
representative samples, the process specifically selected antibodies that could be informa-
tive for a given application, such as the discrimination of pancreatic tumour from healthy
tissue. Actually, there could well be more ’good’ antibodies in the set of 456 molecules,
useful for analyses other than that of pancreatic and bladder tissues. The strategy is most
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suited for a targeted binder selection process. The array format permits flexibility with
respect to the number of molecules that could be studied. This number and the degree
of selectivity of the microarray assay can be adapted to both the actual needs and the
capacity for the subsequent, much more laborious binder characterisation. Similarly, at
the other end, the stringency of the pre-selection process, through panning the original
binder library against the protein(s) of interest, can be tailored, depending on the capacity
of the array analysis.
Our analysis also demonstrated, unsurprisingly, that further characterisation of the selected
antibodies is essential; the antibody microarray analysis on its own is clearly insufficient
when dealing with molecules of unknown quality. Although there were several antibod-
ies that indicated abundance variations of proteins ITCH and GROASP2, for instance,
this result could not be confirmed during the subsequent antibody characterisation. It is
likely that the relevant antibodies bind to other proteins exhibiting reproducible abundance
variation. Neither when antibodies were applied to the antigen array nor in the reverse ex-
periment, when the individual proteins were incubated on the antibody microarrays, could
specific binding be detected. In our pilot scheme, only a small antigen array was used for
identification of binding specificity. The use of more comprehensive antigen microarrays
would lead to a much better proof of the accurate binding of an antibody to the intended
target or the identification of any cross-binding activity. In vitro production of proteins,
and in particular an in situ synthesis directly on the microarray surface [18], [19] and [20]
permits the production of such complex analysis platforms.
The objective of our study was a demonstration of the utility of the microarray-based se-
lection process. During the course of this, disease related differences in protein abundance
were identified and related antibodies of nanomolar affinity were isolated. However, the
biological information gained from this is too preliminary to draw any conclusions on the
value of GRIP2 or CHFR for diagnosis, for instance. Firstly, the sample number was too
small. Secondly, for a comprehensive analysis, further controls would be essential, such as
samples from chronically inflamed pancreatic tissue. Nevertheless, even in the very limited
setting of the pilot scheme, we succeeded in isolating antibodies that could well be useful
for biologically or biomedically motivated studies. Antibody DM380-JA70-F6, for exam-
ple, is the first monoclonal antibody against GRIP2 according to the Antibodypedia data
repository (version 9 of June 2015; http://www.antibodypedia.com) with information on
1 768 896 antibodies.
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In conclusion, an efficient strategy was established that combines the identification of pro-
tein variations of informative value with the selection of related antibodies from a set of
uncharacterised molecules derived from human antibody gene libraries. Only after the
application of relevant protein samples to the antibody microarray are binders of potential
interest characterised further, so as to isolate appropriately performing antibodies for fur-
ther utilisation. This limits the task of antibody characterisation - a bottleneck in current
antibody production - to antibodies that are informative in a particular biological context
of interest.
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2 Investigation and optimization of
protein microarrays as platform for
the absolute quantification of proteins
Apart from the utilization of protein microarrays for the characterization of antibodies
and identification of drug or biomarker targets, we aimed to develop a microarray-based
diagnostic tool to be used at the point-of-care. The suitability of this platform, to allow
quantitative measurements was successfully demonstrated in chapter one. However, the
underlying quantification principle here was based on a relative comparison of protein
expression levels. In order to be applicable to the measurement of a one ore more individual
biomarkers, an absolute quantification strategy had to be developed. In chapter 2.1., the
optimization of a quick, specific, robust and sensitive method for the absolute measurement
of prostate specific antigen concentrations in blood is described. Furthermore, an approach
to investigate the stability of proteins immobilized on the microarray surface was examined
in chapter 2.2., as the protein functionality also contributes and determines the assay
performance.
2.1 Optimization of a microarray-based method for the
quantification of biomarkers in blood
2.1.1 Abstract
The overall goal of this project was to develop a portable biomarker detection system,
which provides quick results with sufficient sensitivity and is potentially operable in com-
bination with a smartphone. For this purpose, the prostate specific antigen (PSA) as one
of the most established and low abundant protein biomarkers was chosen as model pro-
tein. In this work, different parameters influencing the quantification performance of a
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microarray-based competitive PSA quantification strategy were systematically character-
ized. After the optimization of the major components - detection antibody, presentation
of antigen and incubation time - a method was established, which allows the quantification
of PSA in spiked-in whole blood samples in the range of 1 - 100,000 ng/ml within 15 min-
utes. In this proof-of-concept work, we could further demonstrate a functional multiplexed
quantification of PSA and tumor necrosis factor alpha (TNF-α) with the option to include
additional protein candidates.
2.1.2 Introduction
In medicine, biomarkers are defined as measurable indicators of a disease state. Usually,
the parameter to be measured is the concentration of a specific molecule, which, in the
ideal case, exhibits a low value at the healthy state and can be understood as a sign of
disease development once it exceeds a certain threshold. The monitoring of a biomarker
can be very helpful for any kind of disease as it provides the opportunity to potentially
intervene at a very early disease stage [1]. Biomarkers are not only useful for the detec-
tion of certain diseases but can also provide therapy supporting information e.g. when it
comes to the question which therapy to select or when to switch to another treatment due
to an acquired resistance. These approaches, combining diagnostic as well as therapeutic
concepts, are described with the term precision medicine.
The molecules of interest are often DNA fragments, especially in mutation driven diseases
such as cancer. Taking into account that the translation of DNA into a functional protein
is dependent on many factors and can lead to different protein modifications, each exhibit-
ing a different function, it is of advantage to investigate the proteome and use specific
proteins as biomarker [2, 3]. A drawback of this approach is because, from an analytical
and technical point of view, many proteins exhibit a rather low abundance and cannot be
amplified as it is possible with DNA. Commonly and typically used LC-MS methods fea-
ture a sufficient sensitivity, yet, because of the biological specimen matrix, these methods
are laborious in terms of method development as well as sample preparation and limited
regarding throughput. Therefore, sensitive and robust methods for the multiplexed detec-
tion of proteins are needed.
In order to develop a protein biomarker quantification method, which could be used as
a diagnostic tool, immunoassay strategies seem to offer advantages with respect to their
sensitivity, high specificity and their read-out practicability in a non-laboratory environ-
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ment [4]. A convenient format, especially if a multiplexed analysis is needed, are mi-
croarrays [5]. Amongst the variety of available microarray platforms - planar, bead- or
microtiter-based - the focus was set on planar microarrays in this work.
The immobilization of small protein spots on a functionalized surface allows us to print
a huge amount of different proteins on a rather small area. In this miniaturized fashion,
a relatively small amount of sample material is needed, compared to a microtiter plate.
By this the simultaneous measurement of several parameters of interest in one sample can
be enabled. The protein microarray platform in the form of an antibody microarray is
typically used for quantitative proteomics such as the identification of biomarkers which
had been described in the previous chapter. The quantification strategy used here is a
relative one, which is based on the comparison of protein levels in samples from healthy
and diseased patients. However, for the measurement of an individual biomarker with a
diagnostic tool, an absolute quantification is needed to distinguish if a critical, disease indi-
cating concentration is exceeded. Microarray-based methods, which allowed the detection
of single molecules are described in literature and highlight the suitable sensitivity of this
application [6].
Due to the mentioned advantages of a handy platform and because the read-out of mi-
croarrays can be accomplished with a simple fluorescence detector, we focused on the
development of a portable diagnostic test, which could be employed at the point-of-care
or even by the end user (physician or patient). The development of portable microarray
read-out systems is an emerging field and several systems have already been described in
literature [7–9]. Consequently, it is more of importance to select and develop a suitable im-
munoassay detection format as the test itself can be easily transferred onto present systems.
In this work, the prostate-specific antigen (PSA), a well-established biomarker for prostate
cancer, was selected as model protein to develop and test a microarray-based immunoassay
in the first place. PSA is primarily present in the blood of men at a concentration of 0 - 4
ng/ml in healthy individuals. If the threshold of 4 ng/ml is exceeded, a biopsy is indicated
to check if a carcinoma can be localized, which is the case in about 30 % [10]. As a matter
of fact, our test had to feature a quantifiable range of at least 1 - 10 ng/ml.
Based on findings of our group, a good understanding of general parameters, which influ-
ence the performance of protein microarrays, had been acquired over the time [11,12]. This
includes factors such as spot morphology, spot uniformity, choice of surface functionaliza-
tion and protein attachment methods, but also protein concentration and suitable blocking
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reagents. Nevertheless, as the aim of this project was to develop an absolute quantification
strategy for a limited amount of protein candidates, a refinement for the particular use
was needed. Apart from a conventional ELISA-like sandwich assay, we decided to choose
a competitive quantification strategy (see figure 2.1), because it exhibits the advantage of
an adjustable quantification range [13].
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Figure 2.1: A - Direct quantification in sandwich capture format
A microarray with anti-PSA antibodies is incubated with the PSA sample
solution (illustrated: high, middle and low concentration). After the first
incubation a labeled anti-PSA detection antibody is incubated in a second
step.
B - Competitive quantification
The PSA sample solution (illustrated: high, middle and low concentration) is
mixed with a defined amount of labeled anti-PSA detection antibody. This
mixture is incubated on a microarray with PSA. Depending on the amount of
PSA more or less unbound labeled anti-PSA detection antibody will be
generated and able to bind to the immobilized PSA on the microarray surface.
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The theoretical background of a competitive quantification can be explained by the follow-
ing equations:
If a competitive quantification strategy is employed, a labeled detection antibody is added
to the sample solution containing the antigen of interest. The amount of detection anti-
body (Y) as well as antigen (A) determines the amount of the forming immune complex
YA according to the law of mass action.
[Y ] + [A] −→ [Y A] (2.1)
K =
[Y A]
[Y ] · [A]
(2.2)
In this system, the component with the lower concentration will limit the amount of immune
complexes, so we can transform the equation as a function of the amount of the formed
immune complex:
[Y ] = [Y0]− [Y A] (2.3)
[A] = [A0]− [Y A] (2.4)
if [YA] = x
K =
x
([Y0]− x) · ([A0]− x)
(2.5)
x
[A0]− x
= K[Y0]−Kx (2.6)
In other words:
antigenbound
antigenunbound
= K[Y0]−Kx (2.7)
Equation 2.7 indicates that the equilibrium of bound and unbound antigen is dependent
on the affinity constant K and the initially added amount of the detection antibody [Y0].
If this solution is now incubated on a microarray surface with immobilized antigen, the
unbound amount of detection antibody will also bind to the immobilized antigen.
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2.1.3 Materials and Methods
Table 2.1: Materials and chemicals
Name Description Supplier
DY-649P1 NHS-ester, MW: 1066.10 kD Dyomics
NHS-PEG5k-Biotin bifunctional polyethylene glycol Nanocs
MW: 5 kD
UDP-GalN3 Click-iT Enzymatic Labeling System Kit Thermo Fisher
QD655 quantum dots - SiteClick Antibody Labeling Kit Life Technologies
Triton X-100 Sigma-Aldrich
Tween R© 20 Polysorbate 20 Sigma-Aldrich
NaHCO3 Sigma-Aldrich
DMSO Dimethylsulfoxide Sigma-Aldrich
Nexterion E 2D epoxysilanized glass slide Schott
3D Epoxy 3D epoxysilanized glass slide PolyAn
2D Alkyne 2D alkyne functionalized glass slide PolyAn
3D Alkyne 3D alkyne functionalized glass slide PolyAn
3D Malemide 3D malemide functionalized glass slide PolyAn
Neutravidin neutravidin-coated 2D epoxysilanized glass slide PolyAn
Streptavidin streptavidin-coated 2D epoxysilanized glass slide PolyAn
Coating buffer Coating buffer 10x Candor
Dextrane-based 0.2 M NaHCO3 (pH 8.5), 1 % (w/V) dextran,
spotting buffer (2x) 0.012 % (w/V) Igepal R© CA-630,
100 mM NaCl, 10 mM MgCl2
Glycerol-based 0.4 M NaHPO4 (pH 8.5), 10 % (w/V) glycerol,
spotting buffer (2x) 0.01 % (w/V) sarkosyl
PSA Prostate specific antigen (UniprotID: P07288) Abcam
CHYH2 monoclonal mouse anti-human PSA IgG1 Anogen
TNF-α Tumor necrosis factor alpha (UniprotID: P01375) Biomol
Inflximab anti-TNF-α (UniprotID: DB00065) MSD
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2.1.3.1 Protein modifications
Antibody labeling with DY-649-P1
The detection antibody was labeled using the NHS-ester of the Cy5-like fluorescent dye
DY-649P1. For this purpose, the antibody concentration was adjusted to 1 mg/ml in a
0.1 M NaHCO3 buffer with a pH of 9.0 supplemented with 0.01 % (w/v) Triton X-100.
The dye was dissolved in dry DMSO at 1 mg/ml and added to the protein solution with
a molar ratio of 4 - 32:1 (dye : protein) to reach labeling efficiencies of 1, 2 and 4 dye
molecules per protein. After overnight incubation at 4◦C, the buffer of labeled protein was
exchanged to PBS using Amicon ultra-0.5 centrifugal filter units (Merck Millipore) with a
MWCO of 3 kDa.
Antibody labeling with QD655
Antibodies were labeled with QD655 according to the manufacturer’s protocol provided
with the SiteClick Antibody Labeling Kit.
PSA PEGylation
The PEGylation of PSA was carried out as already described for the antibody labeling.
Instead of a fluorescent dye, NHS-PEG4-N3 or NHS-PEG5k-Biotin was used. The PSA-
PEG-Biotin conjugate could be purified and analyzed using size exclusion chromatography
(ÄKTAexplorer, GE Healthcare, mobile phase: PBS, column: Superdex 200 10/300 GL,
detection: absorption at 280 nm).
2.1.3.2 Protein microarray production
For the preparation of protein microarrays glass slides with different functionalities were
used (see above). Proteins were adjusted to the needed concentration, mixed with twofold
spotting (see table 2.1) and spotted using a MicroGrid II 610 (Biorobotics, USA) contact
printer. Prior to sample incubation, slides were blocked for 1 h with the Candor Blocking
Solution (Candor, Wangen im Allgäu, Germany) and washed with PBS supplemented with
0.05 % (v/v) Tween 20 (Sigma Aldrich) using a Tecan HS 4800 hybridization system (Tecan
Group Ltd., Männedorf, Switzerland).
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2.1.3.3 Sample preparation, microarray incubation, read-out and data analysis
Serial dilution series of PSA were mixed in PBS, blocking solution or spiked into whole
blood from female donors. The sample solutions were diluted 1:1 with blocking solution
containing the detection antibody (CHYH2-DY649P1). The blocked slides were sealed
with ProPlate R© 16-well incubation chambers (Grace Bio Labs). Each well was filled with
70 µL of sample solution and incubated for up to 30 minutes at room temperature. After
incubation, each well was washed separately with PBST (PBS supplemented with 0.05 %
v/v Tween 20) and ddH20. The dried slides were than scanned using a Tecan PowerScanner
(Tecan Group Ltd., Männedorf, Switzerland) and images were analyzed using the GenePix
6.0 microarray analysis software (Axon Instruments, Inc., Union City, CA). The median
spot intensities without background correction were used for the analysis. At least five spots
were averaged per detection area (intraarray). For precise quantifications, the intraarray
averaged values were then again averaged with the values of three separate incubations
(interarray).
2.1.4 Results and discussion
Instead of a sandwich capture immunoassay format, which requires two to three incubation
steps with several detection antibodies, a competitive strategy was chosen as only one
detection antibody and just one incubation step was needed. Furthermore, this approach
offered the opportunity to individually adjust the desired quantification range of each
investigated protein. The two detection principles are opposed in figure 2.2.
In contrast to the sandwich format, the competitive quantification strategy yielded the
highest signal intensities at low PSA concentrations and the lowest intensities at high PSA
concentrations - illustrated in figure 2.2 A and B as well as in the resulting quantification
curves in 2.2 C. The actual quantification range in the competitive setup was defined, but
also limited, by the dynamic range between the zero and the infinite concentration response
asymptote, forming an upper and a lower limit of detection.
Comparing the lower limit of detection (graphical interpretation: inflexion point from
the zero-response asymptote towards increasing or decreasing signal intensities) of both
formats, the competitive strategy showed to be ten times more sensitive than the sandwich
capture format. Yet, for a suitable quantification of PSA, further optimization was needed.
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Figure 2.2: A - Direct quantification in sandwich capture format.
B - Competitive quantification.
C - Resulting quantification curve in sandwich vs. competitive format
(four parameter logistic curve fit).
In the following sections, we describe the investigation of each assay component such as
the detection antibody, the antigen as well as the surface to evaluate its effect on the
assay performance in terms of incubation times, signal intensities, detection limits and
multiplexing characteristics.
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2.1.4.1 Detection antibody
In the chosen format of a competitive quantification, the detection antibody represents
the signal-giving component. Several parameters such as labeling ratio, incubation time
and detection antibody concentration were optimized to enhance the signal intensity and
thereby tune the limit of detection.
Selection of antibody with highest affinity
As described in the theoretical part earlier, the affinity of the used detection antibody as
well as its concentration, had to be considered when optimizing the competitive quantifica-
tion method. Amongst several detection antibodies, the mouse anti-human PSA antibody
with the clone number CHYH2 exhibited the highest affinity with a KD of 8.2 nM and was
therefore chosen for all subsequent experiments.
Labeling of detection antibody
A directly labeled detection antibody was preferred rather than the utilization of a sec-
ondary antibody to keep the number of incubation steps as low as possible. As the fluores-
cent properties of the labeled antibody influence the overall assay sensitivity, it was tested
which labeling strategy provided the highest signal intensities. As depicted in figure 2.3 A,
a fluorescent dye was conjugated to the detection antibody in different dye:protein ratios.
The gained fluorescent intensities of the dye labeled antibody were then compared with a
quantum dot (QD) labeling as seen in figure 2.3 B. Quantum dots are known to exhibit a
fluorescent yield well above the ones of dyes and therefore might be an alternative option
to increase signal intensities.
An increased dye:protein ratio resulted in higher signal intensity (figure 2.3 A). An overla-
beling, which lead to a reduced affinity and binding, was, however, observed at a dye:protein
ratio of 8:1. Consequently, a dye:protein ratio of 4:1 was found to be the most suitable
strategy because the highest signal intensities were achieved here. Moreover, concentration
changes resulted in a more pronounced signal intensity difference and smaller concentration
changes could better be detected.
A site-click quantum dot labeling (quantum dot was conjugated to glycosylation of anti-
body) did not show any superior fluorescent properties in comparison with a dye labeling.
An explanation for this might be the increased size of a quantum dot (26 nm in diam-
eter). During the incubation process, the quantum dot-coupled antibody might behave
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Figure 2.3: Labeling of detection antibody using the Cy5-like fluorescent dye
DY-649P1 (A) or fluorescent quantum dots (B).
Experimental setup: Different concentrations of labeled detection antibody
were incubated on 2D epoxysilanized microarrays with immobilized PSA.
more like a rolling nanoparticle with a size of approximately 36 nm, rather than a free
moving molecule. In this regard, a reduced diffusion rate due to sterical hindrances and
mass transportation limitations might prevent the antibody from binding. Similar obser-
vations are also described and discussed in literature [14].
Other signal increasing methods such as rolling circle amplification or reporter enzymes
for the generation of fluorescent dyes would not have met the requirements of a fast and
reproducible one-step solution for the desired application.
Incubation time
Investigating the incubation time as the most time-consuming step, a compromise between
an adequate signal intensity and a short duration had to be made. The gained results,
represented in figure 2.4, indicate that the steady-state antibody binding capacity was at-
tained after one hour. In contrast to the quickly rising signal intensity, only a moderate
background noise increase was observed. As the signal-to-noise ratio (S/N) did not fur-
ther improve at incubation times beyond fifteen minutes, this incubation time was chosen
for our setup. As discussed by Kusnezow et al. [15], the optimal design of a microarray
assay to compensate kinetic limitations would span an incubation time of several hours.
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Yet, it is also mentioned that prolonged incubation times lead to a pronounced dissocia-
tion. Consequently, a longer incubation time would not necessarily result in a better assay
performance as dissociation processes can be dependent on additional and probably more
uncontrollable parameters. This also applies for washing steps, which in our setup were
reduced to a minimum of two PBST washing steps followed by three rinsing steps with
water at the end of each incubation.
Moreover, choosing a time point not in the plateau level but in the dynamic range, required
an exact incubation time control to enable a precise quantification.
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Figure 2.4: Influence of incubation time on signal intensity
Experimental setup: Labeled detection antibody in a concentration of 3 ng/ml
was incubated for different amounts of time on a 2D epoxysilanized microarray
with immobilized PSA.
Concentration of detection antibody
According to the equation transformation made in the introduction, the concentration of
the detection antibody turned out to be the most influential parameter regarding the quan-
tification range. In theory, an equilibrium between the detection antibody in solution, the
antigen in solution and the immobilized antigen has to be reached. As demonstrated in
figure 2.5, the dynamic range of the sigmoidal competitive quantification curve could be
adjusted by the concentration of detection antibody. Hereby, the inflexion point is de-
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termined by the antibody affinity and defined as the point at which the ratio of antigen
bound and antigen unbound in solution equals 1:1. Given a target concentration of PSA of
0.035 - 0.35 nM (1 -10 ng/ml) in solution, the most suitable concentration of the detection
antibody was at 0.02 nM (3 ng/ml). Lower concentrations would have been thinkable too,
but taking into account that lower concentrations of detection antibody would also result
in a decreased absolute fluorescent signal, a compromise had to be made here.
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Figure 2.5: Effect on the dynamic range using different detection antibody
concentrations
Experimental setup: Each sample of a PSA serial dilution series was incubated
with a defined concentration of labeled detection antibody. Sample mixture
with detection antibody was then given on a 2D epoxysilanized microarray
with immobilized PSA. After washing, fluorescence intensity of each PSA spot
was measured and analyzed. A semilog curve fit was performed for data points
within the dynamic range.
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2.1.4.2 Antigen presentation
Apart from the detection antibody, the presentation of the antigen on the microarray sur-
face was another crucial parameter as the antibody is only able to bind a target structure
which remains recognizable. The concentration of the antigen on the surface was no factor
influencing the quantification performance because, under the assumption that the antigen
is covalently bound to the surface forming a saturated monolayer, the immobilized antigen
functions as a capturing sensor and does not significantly influence the equilibrium in so-
lution.
Thinking of a sensitive and 3D-shaped protein, it would be possible that the antigen’s recog-
nition site could be altered or masked by the immobilization process or on-chip degradation
stress. For this reason, we investigated different effects on the antigen presentation such
as immobilization strategy, spotting buffer, matrix effects and protein stability. These pa-
rameters were studied less to increase the signal intensity but rather to ensure a consistent
test performance.
Slide chemistry
The read-out of fluorescent spots on a microarray surface using a fluorescent scanner results
in an image. As a matter of fact, the actual signal measurement is strongly related to the
field of digital image analysis. According to the Rose criterion a signal-to-noise ratio of
at least 5 is needed to be able to distinguish image features at 100% certainty [16]. This
emphasizes that not only the signal intensity itself, but also the background noise had to
be considered [17].
To evaluate which surface functionalization would be the most suitable, the background sig-
nal intensities of different slide formats was compared. According to figure 2.6, the highest
background noise was measured for 3D-malemide slides. 2D-epoxy, 3D-epoxy, neutravidin
and streptavidin slides exhibited a lower background signal, yet a pronounced coefficient of
variation. Alkyne slides featured the lowest background intensities and because of this the
most appropriate properties. For a proper comparison, signal intensity and signal-to-noise
ratios would be needed in addition. As the attachment of PSA on each surface demanded
for its own immobilization strategy, an independent comparison was not feasible at this
point.
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Figure 2.6: Fluorescence background intensities of different slide coatings
Background measured with buffer blank
Immobilization strategy
Based on the results of our background intensity level test, three different immobilization
strategies, needed for each particular surface functionalization, were investigated. As il-
lustrated in figure 2.7, a random immobilization on 2D epoxysilan slides (A), a surface
coupling on a 2D alkyne slide with an azide modified PSA (B) as well as the connection
of the protein to a 2D streptavidin surface via a spacer (C) were compared.
Immobilization on epoxysilanized slides
An immobilization on epoxysilanized slides does not require any protein modification as
the protein is covalently linked to the surface via free and deprotonated amino functions,
but also to some extent via other nucleophilic thiol and hydroxyl groups.
Click immobilization
For the utilization of alkyne slides, an azide moiety had to be coupled to PSA prior to
immobilization. This was achieved by the coupling of NHS-PEG4-N3 to free amine groups
of the PSA. To click the azide-modified PSA onto an alkyne functionalized surface required
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Figure 2.7: Immobilization strategies
A - Immobilization of unmodified PSA on 2D-epoxysilanzied slide.
B - Azide modification and following ’click’ immobilization on alkyne surface.
C - PSA PEGylation via NHS chemistry and attachment to
streptavidin-coated surface.
copper as catalyst. Copper is known to potentially denature proteins, so it had to be tested
if PSA would remain recognizable when employed. Surface staining of attached proteins
using SyproRuby revealed that PSA could be immobilized via the explained route also indi-
cating that the modification was successful (data not shown). However, the gained results
shown in figure 2.8 A pointed out that PSA degraded under the influence of copper, as it
could not be recognized by the detection antibody anymore. This effect was independent
of the copper concentration. An immobilization was observed if no cooper was added, but
it can be assumed that this was mainly due to an unspecific interaction - as shown in figure
2.8 B, PSA could be attached to the 2D alkyne surface without any modification, too.
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Figure 2.8: Immobilization strategies data
A - Immobilization yield of azide-functionalized PSA on 2D-alkyne surface.
Copper concentration: high = 100 µM, low = 100 nM.
B - Immobilization yield of unmodified and azide-functionalized PSA on
different surfaces. PSA-N3 did not bind on the epoxy surface because free
amine residues were blocked by the modification with NHS-PEG4-N3.
C - SEC chromatogram of PEGylated PSA. D - Immobilization yield of
functionalized PSA on streptavidin surface
Immobilization with spacer
Apart from an oriented immobilization, it was further investigated whether the detection
could be increased if PSA was linked to the surface via a single spacer. In this way, the
protein would be able to float in the sample solution being more accessible for antibodies.
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The immobilization via a spacer demanded for a conjugation with a bifunctional PEG
featuring an amine reactive N-Hydroxysuccinimide (NHS) end for the linkage with PSA
as well as a biotin end to connect it to a streptavidin-coated surface. In this regard, the
PEGylation degree had to be adjusted to ensure a mono-PEGylation as it was assumed
that, due to sterical hindrance, a di-PEGylation would block the antibody from binding.
The PEGylated PSA could be detected and purified employing size exclusion chromatog-
raphy (SEC), as seen in figure 2.8 C. In additional MALDI experiments (data not shown),
we could further confirm that PSA was preferably mono-PEGylated (≈ 33 kDa) if a molar
PEG:PSA ratio of 6:1 was used for conjugation. An increased amount of di-PEGylated
PSA (≈ 39 kDa) was detected at a molar PEG:PSA ratio of 12:1 and di- as well as tri-
PEGylated PSA was generated with a molar ratio of 24:1.
Based on the results represented in figure 2.8 D, the detectability of PSA could not be
increased if anchored to the surface via a 5 kDa PEG spacer. Moreover, the highest recog-
nition was achieved by unmodified PSA, which unspecifically attached to the streptavidin
surface. An explanation might be that the PEG spacer is not rigid enough to hold the pro-
tein in an upright position. In this case, PSA might lay down covered by other PEG chains
comparable with rolled lumber. To confirm this assumption, additional experiments us-
ing time-of-flight secondary ion mass spectrometry (Tof-SIMS) or atomic force microscopy
would have to be carried out [18,19].
Table 2.2: Summarized comparison of different immobilization strategies.
Immobilization Background Modification Modification Detectability
∑
Strategy required yield [+]
2D Alkyne +++ y ++ o 5
3D Alkyne ++ y ++ o 4
2D Epoxy ++ n +++ +++ 8
3D Epoxy o n +++ ++ 5
3D Malemide o n +++ ++ 4
Neutravidin + y + + 2
Streptavidin + y + + 2
Comparing the acquired information on background intensity, modification performance
and achieved detectability for each immobilization strategy, as done in table 2.2, we could
conclude that strategies, which did not require a PSA modification step, exhibited a better
performance. This could also be considered as time and material saving advantage, when
thinking of a multiplexed analysis with many protein candidates. The 2D epoxy surface
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was finally chosen as the best protein detectability could be achieved with unmodified PSA
here and as it provided acceptable background properties.
2.1.4.3 Spotting buffer
The choice of an appropriate spotting buffer depended on the chosen immobilization and
slide chemistry. To this extend, the immobilization of unmodified PSA on a 2D epoxysi-
lanized surface via lysine-related free amine residues demanded for a slightly basic pH
(amount of lysine residues in PSA = 9). Comparing different pH values, the highest im-
mobilization could be confirmed for a pH of 8.5 (figure 2.9).
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Figure 2.9: Influence of pH on PSA immobilization
Testing three different spotting buffer types - a dextran-based, a glycerol-based and a com-
mercially available (unknown formulation) - for the immobilization of PSA, no differences
could be observed regarding the spot morphology and the signal intensity upon detection
with a detection antibody (data not shown). Additional properties to evaluate the per-
formance characteristics of the available spotting buffers would include the capacity to
preserve the on-chip protein stability. To investigate the on-chip protein stability, new
methods had to be developed, which will be described in the following chapter.
2.1.4.4 Matrix effects
Apart from the antigen presentation on the surface, it was further tested if the quantifi-
cation performance was altered in different incubation scenarios. In the desired setup, a
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biomarker quantification would be possible in whole blood to minimize the amount of time
and avoid a sample preprocessing. In this regard, PSA was spiked into whole blood from
female donors as well as into blocking solution. The results, represented in figure 2.10 A,
showed that blood as sample matrix did not alter the quantification performance.
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Figure 2.10: A - Correlation of PSA quantification in CBS vs. in whole blood;
B - Final quantification performance in whole blood.
(Black line = Semilog fit of dynamic range)
In summary, the best quantification results were obtained using unmodified PSA for the
immobilization on a 2D epoxysilanized surface, a detection antibody labeled with 4 fluo-
rophores in a concentration of 3 ng/ml and an incubation time of 15 minutes on the chip.
Based on these findings, a calibration curve with a dynamic quantification range of 1 ng/ml
- 10 µg/ml was generated as presented in figure 2.10 B. As initially mentioned, physio-
logical PSA concentrations range from 0 - 4 ng/ml in healthy men. A PSA concentration
between 4 - 10 ng/ml indicate a confirmatory biopsy and concentrations above 10 ng/mL
are considered critical. With the calibration curve at hand, it is possible to accurately de-
termine whether the PSA concentration is above or below 10 ng/ml. However, for a precise
PSA quantification in the desired concentration range of 1 and 10 ng/ml, the quantifica-
tion performance seemed to be not robust enough as it exhibited a pronounced standard
deviation of signal intensities. This might be due to the fact that the limit of detection was
adjusted to a concentration of 1 ng/ml. In such a competitive setup, the limit of detection
is very much dependent on the equilibrium adjustment between the target protein in the
sample solution, the detection antibody as well as the immobilized target protein on the
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microarray (see equations 2.1 to 2.7). In addition, other parameters such as a potential
multicomplex formation, which consists of several detection antibodies cross-bound to one
analyte molecule (rather than one antibody bound to one analyte molecule), might result
in an increased amount of surface bound detection antibodies. Known as ’hook effect’,
this phenomenon might influence the transition phase, especially at low analyte concentra-
tions, and lead to the pronounced signal intensity variation [20]. For this reason, further
investigations with regard towards reproducibility to control this effect would be needed
in the next steps [21]. This would also include the inclusion of a suitable calibration stan-
dard either as an internal standard in the sample, a technical reference on the chip or a
combination of both [22].
2.1.4.5 Multiplexed Quantification
The previously mentioned advantage of the microarray platform is related to the option of
multiplexing. By the immobilization of many different proteins on a small area, the parallel
testing of multiple analytes in one sample can be enabled, which again can improve the
diagnostic accuracy. In this regard, we were interested in developing a multiplexed assay
for the simultaneous quantification of PSA and the tumor necrosis factor-alpha (TNF-
α). TNF-α exhibits elevated concentrations in patients with rheumatic diseases. Peak
concentrations can reach 100 pg/ml or higher but usually concentrations are in the lower
pg/ml range [23]. However, the combinational investigation of these two parameters might
be very valuable in cancer diagnostics as also discussed by others [24–26] Despite this,
a quantification method for TNF-α was of interest for further tests as described in the
following chapters.
The multiplexed detection of PSA and TNF-α, as represented in figure 2.11, shows that
a simultaneous and comparable quantification of both proteins was possible. Regarding
the quantification performance of PSA, it was possible to achieve a dynamic quantification
range from 0.2 - 500 ng/ml. This trend is similar to the previously described calibration
curve (figure 2.10 B), yet no protein concentrations above 500 ng/ml were used in this
experiment and the dynamic range exhibited a logarithmic rather than a linear decreasing
character. The logarithmic decrease also did not allow a proper four parameter logistic
curve fitting. Therefore, a clear correlation between the single and multiplexed quantifica-
tion performance was not possible here. Even though an altered quantification behavior in
the dynamic range is not to be expected, it would still be possible to generate a separate
PSA quantification calibration curve for the multiplexed setup with TNF-α.
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Figure 2.11: Multiplexed quantification of PSA and TNF-α
Experimental setup: A dilution series in CBS containing PSA and TNF-α
was prepared in a way that the sample with highest PSA concentration
exhibited the lowest TNF-α and vice versa. To each sample a solution with
labeled anti-PSA and anti-TNF-α detection antibody was added and the
mixture was incubated on a microarray surface where PSA as well as TNF-α
had been immobilized.
A less broad quantification range from 0.1 to 4 ng/mL was observed in the case of TNF-α.
A potential reason for the narrow dynamic quantification range might be due to the fact
that infliximab, as the used detection antibody, featured a very high affinity with a KD of
4.2 pM [27]. In this regard, the transitional equilibrium phase might be less pronounced,
especially at the investigated detection antibody concentration. Also, an additional refine-
ment of parameters as performed for PSA and described in this work, might improve this
assay.
Nevertheless, with this proof-of-concept experiment we could demonstrate that a paral-
lel quantification of two proteins in a competitive fashion is possible. In the next steps,
other proteins of interest could be included in such an assay. Interferences in array perfor-
mance are not be expected as long as the detection antibodies specifically recognize their
targets and do not feature any cross-reactivity, neither among each other nor with blood
components.
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2.1.5 Conclusion
Based on the gained results, it could be pointed out that it is possible to quantify PSA
in the desired range of 1 - 10 ng/ml on a microarray platform employing a competitive
quantification strategy. This could be enabled by the optimization of several parameters
such as the detection antibody concentration, its labeling and the on-chip incubation time.
Whereas PSA concentrations above 10 ng/ml can be measured accurately, a precise quan-
tification of concentrations around and below 1 ng/ml still remains difficult to control.
In this regard, a sensitivity increase by an optimized antigen presentation could not be
mediated. Nevertheless, the fact that just a small area is required to perform multiple
measurements within 15 minutes emphasizes the potential to apply this assay in a point-
of-care diagnostic test; portable read-out systems have already been developed and can
easily be used for this purpose. Concerning a valid quantification quality and a poten-
tial shelf life of a protein microarray-based assay, the protein stability states a parameter,
which needs to be studied in further experiments as described in the next chapter.
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2.2 Investigating the stability of proteins immobilized on
microarrays using thioflavin T
2.2.1 Abstract
Preserving the stability of a protein is of outmost importance not only in the development
of a pharmaceutical formulation but also in the development of a immunoassay-related di-
agnostic test to guarantee a valid test performance. Apart from a pharmaceutical formula-
tion, proteins are primarily attached to a solid support, e.g. microtiter plates, membranes,
beads or microarrays, in an immunoassay setup. The amount of surface bound protein is
usually in the lower nanogram range and therefore sensitive and preferably easy methods
are needed to investigate its stability. In the present work, it was investigated whether
thioflavin T, an extrinsic fluorescent dye, which is ’activated’ by the the incorporation
into denatured proteins, could be used as quantitative probe to detect and quantify the
degree of stability loss of proteins, immobilized on a microarray surface. In this regard,
four different protein candidates, representing different protein classes, were immobilized
on a microarray and stored at different conditions. To monitor the degree of functional
loss, the capability to be bound by detection proteins as well as the thioflavin T-associated
fluorescence were measured. The correlation of data points, which were generated by these
two measurement methods, revealed a connection between an increasing loss of protein
functionality and an increasing thioflavin T-associated fluorescence. The suitability to use
thioflavin T as a quantitative probe for the evaluation of the protein stability depended on
the secondary structure of the investigated protein. The developed method offers a conve-
nient and feasible method to determine the degree of protein denaturation on a microarray
surface and could be used for the optimization of storage conditions such as the selection
and optimization of storage buffers.
2.2.2 Introduction
Microarrays offer a versatile platform to perform thousands of individual binding assays
simultaneously. They can be used as DNA but also protein arrays. Arising from DNA
chips, several preparation technologies have been adopted for the preparation of protein
microarrays. Other than the straight-forward immobilization of linear DNA strands, pro-
tein microarrays are quite demanding with regard to their preparation as each protein
represents a different molecule featuring its own diversity of suitable and less suitable im-
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mobilization sites [1]. Apart from the immobilization itself, proteins are per se rather
instable macromolecules in comparison to DNA. Especially during the preparation pro-
cess, influences of humidity, evaporation, dehydration, temperature, pH, stirring, light and
interaction forces with surfaces will stress the protein stability.
In general, investigation of protein stability did not deserved the same attention in diagnos-
tics as in the formulation development of the pharmaceutical industry where tremendous
efforts are made to stabilize sensitive therapeutic proteins [2, 3]. With an expanding in-
terest in protein microarrays as diagnostic application, efforts should also be made here
to better control the quality of such assays. The preserved intactness of the protein in a
diagnostic assay will not only determine the shelf life but more importantly ensure the test
performance, especially in the case of quantitative assays.
Based on advances in pharmaceutics many protein stability analysis methods are known,
yet the biggest challenge, regarding protein microarrays, is to identify and develop simple
methods which are sensitive enough to analyze the few picogram of protein mass which are
printed to the microarray surface.
In this regard, it had to be further clarified which stability indicating parameters are im-
portant in the particular case to select the most appropriate technology. The function of a
protein microarray is to present proteins which can interact with distinct binding partners.
By way of example, the interaction between an antibody and its antigen is very depen-
dent and based on a specific structural sequence, consequently, the intactness of the protein
shape determines its stability in this context. To investigate the shape of a protein, spectro-
scopic methods such as Fourier transform infrared spectroscopy (FTIR), circular dichroism
spectroscopy (CD), nuclear magnetic resonance spectroscopy (NMR) and X-ray diffraction
but also H/D-exchange measurements are typically employed. However, for the analysis of
proteins immobilized on a microarray surface these methods are not feasible as the protein
can only be analyzed in solution (CD, NMR, H/D-exchange) or are not sensitive enough
for the given amount of protein (FTIR). To this extent, more advanced technologies like
X-ray photoelectron spectroscopy (XPS), sum frequency generation (SFG) as well as time
of flight secondary ion mass spectrometry (ToF-SIMS), which can detect the protein con-
formation at the interface of protein and surface would be in favor, yet laborious.
The tertiary structure and conformation of a protein is furthermore dependent on the un-
derlying chemical stability. Therefore, methods which allow to monitor chemical changes
(denaturation, oxidation, deamidation) can be used to predict conformational changes
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too [4]. An alternative and very inexpensive approach to characterize proteins is the in-
vestigation of fluorescence-based parameters such as the intrinsic tryptophan fluorescence
or the interaction of extrinsic fluorescent dyes with denatured proteins. These dyes e.g.
are used to visualize the formation of amyloid fibrils related to neurodegenerative diseases
such as Alzheimer’s disease [5, 6]. A list of suitable and available dyes featuring different
properties has been summarized by Hawe et al. [7].
The aim of this work is to investigate the functional stability of proteins immobilized on a
microarray surface by means of detectability using a corresponding binding partner and to
establish a method which allows to monitor the chemical and the related conformational
stability of proteins using an extrinsic fluorescent dye. For this purpose, a correlation be-
tween loss of antibody/antigen recognition and increase in denaturation-based thioflavin
T (ThioT) fluorescence had been elaborated. With the developed tool at hand, it will
be possible to improve the evaluation of immobilization procedures because the basis of
valuation could then be complemented by the stability factor.
2.2.3 Materials and Methods
Table 2.3: Utilized proteins
Protein Class MW Disulfide Glyco. Uniprot ID/
[kDa] bonds sites Accession no.
Im
m
o
b
il
iz
a
ti
o
n PSA enzyme 28.7 5 1 P07288
TNF-α cytokine 25.6 1 1 P01375
Infliximab IgG1 149.1 16 2 DB00065
DM380 JA70-F6 scFv-Fc 110 12 2 n.a.
(anti-GRIP2) (fusion protein)
D
e
te
ct
io
n
anti-PSA IgG1 150 n.a.
(clone: CHYH2) (mouse anti-human)
Infliximab IgG1 149.1 DB00065
TNF-α cytokine 25.6 P01375
GRIP2 Glutamate receptor 112.5 Q9C0E4
-interacting protein 2
The following chemicals were obtained from Sigma-Aldrich: Thioflavin T (CAS# 2390-
48
54-7), Glycerol 86 % (w/V, CAS# 56-81-5), Sarkosyl (CAS# 137-16-6), Igepal R© CA-630
(CAS# 9002-93-1), Tween R© 20 (CAS# 9005-64-5), dextran (enzym. synthesis, CAS#
9004-54-0) as well as all salts NaHPO4, NaCl, MgCl2, NaHCO3.
Detection proteins were labeled with the Cy5-like fluorescent dye DY-649-P1 (Dyomics
GmbH, Jena, Germany) via NHS-chemistry in a molar ratio of 12:1 (dye:protein).
2.2.3.1 Protein microarray preparation and storage
For the preparation of protein microarrays epoxysilanized glass slides (Nexterion E, Schott,
Jena, Germany) were used. The investigated proteins are listed in table 1. Each protein
solution was adjusted to a concentration of 1 mg/ml, mixed with twofold spotting buffer
(glycerol-based: 0.4 M NaHPO4, pH 8.6, 10% glycerol, 0.01% sarkosyl; dextran-based: 0.2
M NaHCO3, 1 % (w/V) dextran, 100 mM NaCl, 10 mM MgCl2, 0.012 % (w/V) Igepal CA-
630 ) and spotted using a MicroGrid II 610 (Apogent Discoveries, Mittenwald, Germany)
contact printer equipped with SMP6B pins (Arrayit). Thus, droplets with a volume of
0.6 nl featuring spots of around 220 µm in diameter were generated. In each incubation
block (0.7 x 0.7 cm) 15 spots of one protein in one spotting buffer with a spot-to-spot
distance of 1.5 mm were printed (4 proteins x 2 spotting buffers = 8 incubation blocks,
each with 15 spots). Prior to sample incubation, slides were blocked for 1 h with the Candor
Blocking Solution (Candor, Wangen im Allgäu, Germany) and washed with PBST (PBS
supplemented with 0.5 % (v/v) Tween 20 using a Tecan HS 4800 hybridization system
(Tecan Group Ltd., Männedorf, Switzerland). The prepared slides were then packed in
air-proof bags with drying silica gel pearls (blue, Sigma Aldrich) and stored at -20, 4, 25
and 60 ◦C for 1, 7, 30 and 90 days.
2.2.3.2 Incubation and analysis of samples - Antibody/antigen recognition
The blocked slides were sealed with ProPlate R© 16-well incubation chambers (Grace Bio
Labs). Each well was filled with 70 µl of detection solution (corresponding detection
proteins labeled with DY-649-P1 dissolved in the blocking solution at a concentration
of 100 ng/ml) and incubated for 15 min at room temperature. After incubation, each
well was washed separately with PBST as well as ddH2O for three times and dried with
pressurized air. The dried slides were than scanned using a Tecan PowerScanner (Tecan
Group Ltd., Männedorf, Switzerland) and images were analyzed using the GenePix 6.0
microarray analysis software (Axon Instruments, Inc., Union City, CA).The median spot
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intensities without background correction were used for further data analysis.
2.2.3.3 Incubation and analysis of samples - Thioflavin T fluorescence
Similar to the procedure described above, a fresh solution of Thioflavin T (0.5 mM in
PBS) was produced and 70 µl of this solution were added to each well. After an incubation
of 30 minutes protected from light, microarray slides were rinsed with ddH2O for three
times. The resulting fluorescence was measured using a SensoSpot Fluorescence Microarray
Analyzer (Sensovation, AG, Radolfzell, Germany).
2.2.4 Results and discussion
Protein microarrays, as an alternative platform for immunoassays, rely on the formation of
antigen-antibody complexes. In the ideal case, the immobilization as well as the storage of
proteins on microarray surfaces should not alter the protein in its ability to form immune
complexes. However, since the protein interacts with the microarray surface and is exposed
to external denaturation stresses such as humidity and temperature changes, it is likely
that the protein undergoes conformational transformations. To assess conditions, which
prevent or accelerate a protein’s denaturation when immobilized on a microarray surface,
it was of prior importance to develop suitable methods which allowed an investigation of
the on-chip protein stability.
In this regard, two methods were employed and compared:
1. Antigen/antibody detectability - To investigate to which extent a protein loses func-
tionality on the microarray surface, it was measured and compared how much of the cor-
responding binding partner could still be bound after storage. Simulating a controlled
microarray experiment, this method was used as our reference method. It allowed us to
quantify the loss of function. In this context, the loss of function should be understood as
a general loss of protein detectability preferably due to conformational alterations.
2. Thioflavin T fluorescence - The extrinsic fluorescent dye thioflavin T is known to incor-
porate into the hydrophobic sites of denatured proteins - preferably β-sheet-rich amyloid
fibrils [8,9] - and it is widely used already in protein formulation analytics to detect confor-
mational changes at rather early stages. Despite this, it had never been tested whether this
approach is sensitive enough to monitor conformational changes on microarray surfaces.
We hypothesized that the degree of function loss of an immobilized protein correlates with
an increasing thioflavin T fluorescence, in a way that thioflavin T might be used as a
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quantitative probe.
As stability characteristics may vary from protein to protein, four candidates, representing
different protein classes, were chosen and investigated in this study. Prostate specific anti-
gen (PSA), tumor necrosis factor alpha (TNF-α), infliximab and a scFv-Fc fusion protein
(properties listed in table 2.3) were spotted on epoxysilanized microarray slides using a
glycerol- as well as a dextran-based spotting buffer. The prepared slides were then stored
at -20, 4, 25 and 60 ◦C for 1, 7, 30 and 90 days.
2.2.4.1 Antibody/antigen detectability
To illustrate the loss of protein functionality after immobilization on a microarray surface
and the resulting loss of detectability by the corresponding binding partner an exemplary
data set is shown in figure 2.12. The data points represent the relative amounts of how
much antigen could be bound by the immobilized antibody-like scFv-Fc fusion protein
after 1, 7, 30 and 90 days of storage at a storage temperature of 4 ◦C.
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Figure 2.12: Loss of protein recognition over time
The monoclonal IgG1 antibody infliximab was immobilized on a microarray
surface (glycerol-based spotting buffer), stored at different temperatures and
detected with DY-649-P1-labeled TNF-α after different time points.
Over a time interval of 90 days, a protein recognition decrease of 37.1 % was observed if the
protein microarray was stored at -20 ◦C. At a storage temperature of 4 ◦C the degradation
rate and degree was comparable. If stored at 20 and 60 ◦C hardly any recognition could
be measured after one day of storage (a time point t0, which would have been immediately
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after printing, was not feasible as at least 24 h were needed for the protein to immobilize).
The fact that the protein detectability could not be preserved neither at -20 ◦C nor at 4
◦C implied the sensitivity of this particular protein.
2.2.4.2 Thioflavin T fluorescence
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Figure 2.13: Thioflavin T as fluorescent denaturation probe
A - Thioflavin T fluorescence in solution (excitation: 440 nm), Infliximab
was diluted in PBS at a concentration of 1 mg/ml. The denatured specimen
was analyzed after a storage over three days at 60 ◦C. Measured with Tecan
infinite M200 plate reader.
B - Fluorescence scan of antibody microarray with 660 entities stored at
different temperatures for three days. Measured with SensoSpot Fluorescence
Microarray Analyzer (Sensovation).
The reason why thioflavin T was chosen as indicative dye was mainly due to its fluorescent
properties (excitation: 440 nm, emission max.: 475 - 495). Typically, microarray scanners
feature a green (580 ± 21 nm) and a red (675 ± 18 nm) filter setting for the measurement
of Cy3 and Cy5-like dyes. The SensoSpot Fluorescence Microarray Analyzer (Sensovation)
was equipped with an additional blue filter setting (500 ± 15 nm) allowing to quantify the
amount of thioflavin T fluorescence on the microarray surface. Illustrated in figure 2.13
A and B, an increase in degradation-dependent fluorescence could be observed in solution
using a Tecan infinite M200 fluorescence plate reader as well as on the protein microarray
surface using the SensoSpot Fluorescence Microarray Analyzer.
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2.2.4.3 Analysis of on-chip protein stability
In the following sections, the gained findings are summarized by opposing the results from
the two employed methods, separately for each protein and each storage temperature.
PSA
The observed results represented in figure 2.14 indicate that temperature and storage stress
did not have a pronounced effect on the recognition of PSA by the used detection antibody.
Moreover, instead of a function loss, an increasing recognition trend independent of the
storage temperature seemed to be the case. Also, the choice of the used spotting buffer
did not show a major difference in recognition performance.
Regarding the measured thioflavin T fluorescence, an elevating signal intensity was seen
if PSA was stored in the glycerol-based spotting buffer. This effect was more pronounced
the higher the selected storage temperature. If PSA was spotted with the dextran-based
buffer hardly any increase in thioflavin T fluorescence could be achieved.
TNF-α
Similar to the previously specified function loss properties of PSA, TNF-α exhibited an
increasing or constant recognition behavior at storage temperatures of -20 and 4◦C respec-
tively. This effect was independent and comparable amongst the two employed spotting
buffer systems. However, a tremendous loss of detectability was observed if TNF-α was
stored in the glycerol spotting buffer at higher temperatures. At 25 ◦C a loss of 74.7 %
within seven days was recorded, whereas hardly any protein remained detectable from day
one on if stored at 60◦C.
In contrast to PSA, a trend, exhibiting an increasing thioflavin T fluorescence with de-
creasing protein recognition was monitored for TNF-α. This was particularly the case at
storage temperatures above 4◦C. Nevertheless, it has to be put into question whether the
signal intensity jump of the specimens at 60◦C day 7, stating the overall maximum, could
also be considered as measurement error or outlier as this effect was also seen in the follow-
ing analysis. A possible explanation might also be that after a one month storage at 60◦C
only minor protein residues, which would allow thioflavin T incorporation, are present.
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Infliximab
Other than PSA and TNF-α, infliximab is a therapeutic anti-TNF-α monoclonal IgG1-type
antibody used for the treatment of rheumatic patients. Investigating its on-chip stability,
revealed that the antibody structure was more likely to lose its function. Even at storage
temperatures of -20 and 4◦C a loss of up to 50.5 % was measured. It was further noticed
that the utilization of the dextran-based spotting buffer seemed to provide a slight stability
preserving effect.
ScFv-Fc fusion protein
As previously mentioned, the antibody-like scFv-Fc fusion protein exhibited the most sen-
sitive stability characteristics amongst all investigates proteins as a strong loss of function
could already be noticed if stored in a glycerol environment at 4◦C for seven days. However,
with a closer look at the measured binding capacity at a storage temperature of 25◦C, the
employment of the dextran-based spotting buffer was able to better preserve the protein’s
stability.
Similar to the observations made in the case of infliximab, a higher degree of denaturation
lead to an, in average, higher thioflavin T intensity.
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Figure 2.14: PSA
Degree of protein function loss vs. degree of thioflavin T incorporation and
resulting fluorescence due to storage and temperature stress. Values were
normalized to the maximal fluorescent intensity of all measured values.
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(Ag/Ab rec. = antigen/antibody recognition, ThioT Fl. = Thioflavin T fluorescence)
Figure 2.15: TNF-α
Degree of protein function loss vs. degree of thioflavin T incorporation and
resulting fluorescence due to storage and temperature stress. Values were
normalized to the maximal fluorescent intensity of all measured values.
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Figure 2.16: Infliximab
Degree of protein function loss vs. degree of thioflavin T incorporation and
resulting fluorescence due to storage and temperature stress. Values were
normalized to the maximal fluorescent intensity of all measured values.
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(Ag/Ab rec. = antigen/antibody recognition, ThioT Fl. = Thioflavin T fluorescence)
Figure 2.17: ScFv-Fc fusion protein
Degree of protein function loss vs. degree of thioflavin T incorporation and
resulting fluorescence due to storage and temperature stress. Values were
normalized to the maximal fluorescent intensity of all measured values.
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In summary, PSA and TNF-α could still be well recognized after a 90-days storage if kept
at typically temperature conditions of -20 and 4◦C. PSA did not lose its function even at
elevated storage temperatures of 25 and 60◦C. A reason for this might be due to the fact
that the used PSA detection antibody was directed against a linear peptide epitope. In
this case, it is less of relevance whether a protein exhibits an intact structure or not. For
the recognition of the more temperature sensitive TNF-α, infliximab was used as detection
antibody. The underlying immune complex formation here seemed to be more dependent
on an intact three-dimensional structure of TNF-α, which is well in accordance with find-
ings on the binding geometry of infliximab and TNF [10].
In contrast, an on-going degradation was observed in the case of the infliximab antibody
as well as the scFv-Fc fusion protein. It is arguable whether this loss of functionality
was only dependent on storage effects (humidity, spotting matrix, temperature) or also
on immobilization effects. As the storage conditions at -20 and 4◦C represented a protein
stability maintaining environment, we hypothesized that the functional loss was a more
immobilization-dependent process. An increased molecular weight of the antibody and the
scFv-Fc fusion protein offers a higher amount of potential interaction sites between pro-
tein and surface such as nucleophilic lysine, thiol and hydroxyl groups. Consequently, and
because the epoxysilanized surface had not been blocked prior to storage, it was assumed
that the proteins continuously bind to the reactive surface and by this are stretched out
on the solid support. Technically, it would have been easy to reduce or deactivate the
functional epoxy residues by blocking as emphasized by others [11]. Apparently, the visual
appearance of the spotting pattern is then washed away and a visual inspection, which is
needed for handling and orientation purposes, cannot be carried out anymore.
Drawing a comparison to other surface bound protein techniques such as Western Blot
or ELISA, it seemed to be less problematic to present an antigen in a way that it can
be recognized by an antibody rather than immobilizing an antibody and maintaining its
active function of binding antigens. Even though an antigen might lose its native three-
dimensional structure and stretches out on the surface, the corresponding detection anti-
body might still be able to bind to its epitope. This might be the case especially, if it is an
antibody which is known to be suitable for applications such as Western blot or IHC. In
contrast, it should be considered that even if an antigen remained detectable, this does not
automatically imply that the protein did not degrade. This fact could be of importance if
an antigen microarray is used to detect antibodies, which only recognize their target in its
native three-dimensional structure as previously discussed in chapter I.
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Looking at the measured thioflavin T fluorescence values, without a correlative comparison
with the antigen/antibody recognition results at this point, increasing fluorescence values
were achieved the longer proteins were stored and the higher the storage temperature was
set. This was observed for all investigated protein candidates and is in good accordance
with the findings in figure 2.13 B. In addition, it is striking that the thioflavin T fluores-
cence intensity jumped from day one to day seven in the case of TNF-α, infliximab and the
scFv-Fc fusion protein, especially if kept at 25 or 60◦C. An explanation for this might be
that the proteins denature within seven days and in the following twenty-three days then
reach a state beyond denaturation, which is determined by a more hydrophilic character
due to oxidation procedures hindering the thioflavin T to incorporate.
A detailed correlation between function loss and thioflavin T fluorescence is discussed in
the next section.
2.2.4.4 Correlation of antigen/antibody recognition vs. thioflavin T fluorescence
Correlating the gained thioflavin T fluorescence with the achieved signal intensities of the
detection assay allowed us to evaluate the hypothesis if a thioflavin T-associated fluores-
cence is quantitatively correlated with a loss of detectability. For the correlation displayed
in figure 2.18, the raw signal intensities of the detection assay are opposed with the gained
raw thioflavin T fluorescence values. In more detail, all values in regard of spotting buffer,
storage time and storage temperature were used for the analysis of each protein. However,
data points after a 7-day storage at 60◦C were, based on Grubbs testing and graphical
interpretation, considered as outliers and excluded from the correlation analysis.
Testing on a confidence interval of 95 %, a significant correlation could be pointed out
in the case of PSA (p-value = 0.0005), TNF-α (p-value = 0.0008) and infliximab (p-
value < 0.0001); no correlation was observed for the scFv-Fc fusion protein (p-value =
0.2366). Whereas data on TNF-α and infliximab confirmed a negative correlation between
detectability and thioflavin T fluorescence (rTNF-α= -0.53 , rinfliximab= -0.67) as initially
expected, PSA exhibited a positive correlation (rPSA= 0.58).
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Figure 2.18: Correlation of antigen/antibody recognition and thioflavin T
fluorescence
Correlation of antigen/antibody recognition and thioflavin T fluorescence
with all measured data points over time and temperatures. Data points in
orange were considered as outlier (graphical interpretation + Grubbs test)
and not included into the correlation analysis.
P-values:
PSA = 0.0005, TNF-α = 0.0008, Infliximab < 0.0001, scFv-Fc = 0.2366.
With a closer look at the molecular properties of the investigated proteins and discussing
the incorporation mechanism of thioflavin T on this level, it might be able to generate a
better understanding why the correlation might be more significant in the case of inflix-
imab rather than for TNF-α, PSA or the scFv-Fc fusion protein.
The underlying principle of thioflavin T incorporation implies a dynamic and potentially
irreversible change in the secondary protein structure. Consequently, a good correlation
indicates that those thioflavin T-sensitive secondary structure alterations are linked to and
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determine the binding affinity of the detection antibody.
The monoclonal IgG1 antibody infliximab is composed of several β-sheet structures within
its heavy and light chains which makes thioflavin T a suitable dye to assess the conforma-
tional as well as colloidal stability as indicated by Tim Menzen [12].
As reported by Narhi et al., unfolded TNF-α contains only β-sheet structures, which par-
tially transform into irreversible α-helical aggregates through thermodynamically induced
denaturation processes [13]. These structural changes seem to create a hydrophobic and
therefore thioflavin T friendly environment. Taking the secondary structure-based binding
geometry of the TNF/infliximab complex into account [10], these findings also lead to the
conclusion that a correlation between thioflavin t-associated fluorescence, protein stability
as well as detectability is possible which is in good accordance with our results.
Other than that, an increased thioflavin T-associated fluorescence of PSA seemed to dis-
play a more non-denatured state. However, since PSA remained detectable even after a
90-day-storage at 60◦C, it had to be concluded that the recognition site of the detection
antibody is independent of the stability of the protein, which can be confirmed as the used
detection antibody is also suitable to detect linearized PSA on nitrocellulose membrane in
Western blot experiments.
Based on the gained results for infliximab, similar findings were expected for the IgG1
antibody-like scFv-Fc fusion protein. According to Jaeger et al. the single chain fragment
variables (scFv), consisting only of the variable regions of the immunoglobulin light and
heavy chain were connected to the IgG Fc moiety by a soluble and flexible oligopeptide
forming the scFv-Fc fusion protein [14]. The interpretation of our data, represented in
figure 2.12 already revealed that the scFv-Fc fusion protein was much more temperature-
sensitive than infliximab which might be due to a less condensed structure. As a conse-
quence, the amount of thioflavin T, which is able to incorporate into denatured scFv-Fc
protein, is limited.
In summary, we concluded that each investigated protein exhibited its own specific de-
naturation characteristic. Furthermore, the ability to monitor this denaturation process
using thioflavin t is very dependent on the structure of the protein itself but also on the
used detection protein. As already discussed by others, an underlying β-sheet assembly
seems to be a basic requirement to employ this assay. Despite this, our results showed
that thioflavin T in general is a simple, quick and cost-saving method which can be used
to monitor the degree of denaturation once the specific denaturation characteristics of the
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protein are known.
2.2.4.5 Comparison of two different spotting buffers
The employed methods and obtained results were also used to compare two different spot-
ting buffers: a glycerol-based as well as a dextran-based system. In the previous chapter,
the importance of the spotting buffer was already emphasized - the composition of differ-
ent excipients determines parameters such as spot size, spot morphology, immobilization
efficiency, evaporation but also protein stability. With regards towards their spotting per-
formance, the investigated spotting buffer exhibited good results. However, less was known
about their capacity to preserve the protein stability on the microarray surface.
For the comparison of the stability preserving performance of the two buffers, the anti-
gen/antibody recognition as well as the thioflavin T fluorescence could be used. However,
due to a non-Arrhenius behavior (involvement of too many influential parameters) it was
not possible to calculate and compare time- and temperature-independent kinetic con-
stants. As a matter of fact, the area under the curve (AUC) was calculated for each
protein separately for each spotting buffer and temperature. The values were added over
time and normalized to the overall sum. By this, it was possible to compare which spot-
ting buffer provided the higher antigen/antibody recognition or thioflavin T fluorescence
at different storage temperatures as seen in figure 2.19.
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Figure 2.19: Comparison of spotting buffer performance
By means of normalized AUC values.
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Based on these findings, it was possible to determine that, except for PSA, the dextran-
based spotting buffer featured the overall superior protein preserving properties. For TNF-
α, infliximab and the scFv-Fc fusion protein a higher detectability and a lower thioflavin
T fluorescence, also in a storage temperature resolved manner, was calculated. Regarding
the evaluation of PSA, it has to be keept in mind that, in contrast to the other candidates,
a higher thioflavin T-associated fluorescence indicated a better recognizable protein.
Nevertheless, concerning practicability aspects such as spot morphology, glycerol-based
spotting buffer systems are reported to provide beneficial properties especially with regard
towards microarray printing [15, 16]. Dextran-based systems, which are commonly used
in surface plasmon resonance measurements, are well known for their stabilizing capacity.
Nevertheless, it should be mentioned that these buffers are less used for spotting rather
than for coatings [17–19].
2.2.5 Conclusion
In the present work, it was demonstrated that thioflavin T is an appropriate probe to de-
tect protein denaturation process not only in solution but also for proteins immobilized on
microarray surfaces. A significant negative correlation between protein detectability and
thioflavin T fluorescence could be pointed out for two of the four investigated proteins.
Regarding its potential to serve as a quantitative protein function loss indicator, our cor-
relation analysis showed that it depends on the protein to be investigated as well as the
utilized detection protein, in particular the underlying secondary protein structure (e.g.
β-sheet rich regions). It would have been of further interest to compare the gained results
with results achieved using alternative techniques. Unfortunately, no useable results could
be generated neither with time-of-flight secondary ion mass spectrometry nor with sum
frequency generation. This emphasizes the importance of the developed method at hand,
which allowed us to investigate and characterize the on-chip protein stability in a feasible
fashion. In this regard, it was finally shown that a dextran-based spotting buffer features
an improved stabilization performance in comparison to a glycerol-based matrix.
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3 Assay development for the
immunological quantification of
therapeutic antibodies and anti-drug
antibodies
The evidence obtained by the investigations described in the previous chapters - antibody
characterization and optimization of quantitative immunoassay - were used to design an
applicable immunoassay for the analysis of clinical samples. In this regard, the detection
of anti-drug antibodies was addressed.
In chapter 3.1. a microarray-based strategy is described, which can be implemented into
existing portable microarray read out systems, whereas in chapter 3.2. a smartphone at-
tachable blood glucose meter was used as read-out system.
All experiments as well as the drafting of the manuscripts was done by Janek Kibat.
Chapter 3.2. was submitted to PLOS ONE in April 2017.
Janek Kibat, Christian Bauer, Malte Buchholz, Thomas Gress, Christoph Schröder, Ger-
hard Winter and Jörg D. Hoheisel‡, Quantification in plasma of the protein drugs inflix-
imab and adalimumab as well as the patients’ corresponding immune response using a
smartphone-attachable blood glucose meter. PLOS ONE.
‡ Corresponding author
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3.1 Simultaneous quantification of Infliximab,
adalimumab and corresponding anti-drug antibodies
in plasma using protein microarrays.
3.1.1 Abstract
From a pharmacological point of view, a therapeutic drug monitoring of biological drugs
such as proteins is of essential importance, not only to control the drug level and its effec-
tiveness but also to investigate a potential abundance of anti-drug antibodies (ADAs). By
means of humanized protein engineering, formulation design and administration schedules,
the occurrence of ADAs might be minimized. Nevertheless, as therapeutic proteins can be
understood as a foreign body, an immunogenicity potential remains. This risk is especially
elevated in rheumatic patients which are under permanent treatment. In this work, we
developed and optimized a microarray-based drug monitoring test for adalimumab and
infliximab, which combines several individual assays such as drug type and drug concen-
tration determination as well as IgG- and IgM-ADA quantification. The test performance
allows a drug quantification within a range of 0.01 to 4 µg/ml (competitive strategy) and
an ADA quantification starting from 10 to 10,000 ng/ml (bridging format) with a free drug
tolerance of 1 µg/ml. The assay was further employed for the analysis of clinical patient
samples to test its applicability and performance.
3.1.2 Introduction
The administration of highly specific therapeutic proteins is part of the state-of-the-art
treatment options for many diseases such as cancer, hemophilia, anemia, diabetes as well as
rheumatic and infectious diseases. However, the formation of anti-drug antibodies (ADA)
is a potential risk, limiting the applicability of biological drugs especially if given over a
longer period of time [1]. The risk can be reduced if the active protein is well designed and
exhibits a low immunogenicity or if the patient is additionally treated with immunosuppres-
sive drugs [2, 3]. Aside from the protein engineering and the therapeutical strategy itself,
the inclusion of a diagnostic strategy is needed to detect and to handle this complication
adequately. In the ideal case, the patient is under continuous monitoring which includes
both, a therapeutic drug monitoring as well as an evaluation of ADA concentrations [4–6].
By this, the drug plasma concentration could be precisely adjusted to avoid overdosing
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(which could again trigger the formation of ADAs) and alternative therapy concepts could
be selected before a full drug resistance would have regarded by the patient [5,7–9]. Apart
from an increased therapy effectiveness, an appropriate therapy monitoring would also
reduce the amount of needless injections e.g. when it comes to overdosing due to an unex-
pectedly low elimination or in the treatment of drug-resistant patients and would therefore
also reduce costs [10,11].
The detection of ADAs in plasma samples from patients, especially from those who are
currently under treatment, is a challenging task. This is due to the fact that the ma-
jority of ADAs will be bound to the present drug and thereby are hardly accessible in
an immunological assay without immune complex dissociation. Furthermore, the data in-
terpretation is not always clear in a way that it might be difficult to assess whether the
amount of detected ADAs represents a clinical relevant immune response. In this context,
it is not just one specific ADA rather than a patient-individual collection of different an-
tibody isotypes against different epitopes. Amongst all ADAs, preferably the neutralizing
candidates, which are directed against the functional epitope of the drug, are the ones
limiting the pharmacological function most.
By now, many techniques and data analysis tools have been published, describing how to
circumvent or control influencing factors and how to approach a valid ADA quantifica-
tion [12–14]. The experimental setup can be quite laborious, especially if an isotyping is
pursued. For a patient-individual and continuous monitoring, also known as personalized
medicine, a reliable test is needed, which can be carried out in a clinical routine setting.
The requirements for such a clinical use would comprise a short test duration, basic labo-
ratory equipment as well as the possibility to implement it into an automated process.
With respect to the mentioned aspects and being aware of interfering parameters, a protein
microarray-based method was developed, which combines the quantification of drug levels,
the determination of related ADA concentrations as well as the differentiation between
an IgM or IgG predominant immune reaction in one assay. As protein microarrays offer
a suitable platform for more than just one drug, we designed a proof-of-concept test for
the two most widely used anti-rheumatic drugs - adalimumab and infliximab [15, 16]. By
multiplexed combinations it was possible to answer the following questions when analyzing
patient samples: Is drug present in the sample? If yes, which drug is present and how
high is its concentration? Are ADAs present? If yes, against which drug and in which
concentration? Which ADA isotypes can be detected?
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After testing the assay performance in terms of limit of detection, drug tolerance level
and correlation with ELISA results using surrogate ADAs, clinical patient samples could
be analyzed. The obtained samples from rheumatic Crohn’s disease (MC) and ulcerative
colitis (UC) patients under adalimumab and infliximab treatment were used to test the
assay applicability and to evaluate clinically relevant ADA concentrations.
3.1.3 Materials and Methods
3.1.3.1 Protein microarray preparation
For the preparation of protein microarrays epoxysilanized glass slides (Nexterion E, Schott,
Jena, Germany) were used. Adalimumab (Humira R©; Abbvie Ltd.), Infliximab (Remicarde R©,
MSD Sharp & Dohme GmbH), HCA203, HCA213, (AbD Serotec - Bio-Rad Laboratories
Inc.), TNF-α (ATGen Ltd) as well as human IgM (myeloma, whole molecule, Thermo
Fisher Scientific) were adjusted to the needed concentration, mixed with twofold spotting
buffer (0.4 M NaHPO4, pH 8.6, 10% glycerol, 0.01% sarkosyl) and spotted using a Micro-
Grid II 610 (Apogent Discoveries, Mittenwald, Germany) contact printer. Prior to sample
incubation, slides were blocked for 1 h with the Candor Blocking Solution (Candor, Wan-
gen im Allgäu, Germany) and washed with 1 M glycine buffer (pH 2.6) supplemented with
1.0 % (v/v) Tween 20 (Sigma Aldrich) using a Tecan HS 4800 hybridization system (Tecan
Group Ltd., Männedorf, Switzerland).
3.1.3.2 Incubation and analysis of samples
Serial dilution series of adalimumab, infliximab, anti-adalimumab (HCA203) or anti-infliximab
(HCA213) were spiked in the pooled plasma of 5 healthy individuals. These sample so-
lutions as well as the patient plasma samples were diluted 1:1 in blocking solution. The
blocked slides were sealed with ProPlate R© 16-well incubation chambers (Grace Bio Labs).
Each well was filled with 70 µL of sample solution and incubated for 1 hour at room tem-
perature. Prior to the incubation with 70 µL of detection solution, each well was washed
with PBST (PBS supplemented with 0.05 % v/v Tween 20) for three times. The detec-
tion solution consisted of adalimumab and infliximab labeled with DY-649-P1 (Dyomics
GmbH, Jena, Germany) each at a concentration of 0.05 µg/ml dissolved in the blocking
solution. Each well was washed separately with PBST and ddH2O after 1 hour incu-
bation. The dried slides were than scanned using a Tecan PowerScanner (Tecan Group
Ltd., Männedorf, Switzerland) and images were analyzed using the GenePix 6.0 microarray
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analysis software (Axon Instruments, Inc., Union City, CA).
3.1.3.3 Drug tolerance
Plasma samples were spiked with HCA203 and HCA213 at a constant concentration of 250
ng/ml and different drug concentrations form 1 mg/ml to 10 ng/ml. Samples were then
further processed as described above.
3.1.3.4 ELISA
ELISA experiments were used as reference method for the quantification of drug and anti-
drug antibody levels. 50 µL of a solution containing 5 µg/ml TNF-α, adalimumab or
infliximab were filled in each well of a 96-well microtiterplate (Maxisorb; Nunc, Roskilde,
Denmark) and incubated overnight at 4◦C. The following day, the protein solution in the
wells was discarded and wells were blocked with 150 µL of 5 % (w/v) skim milk for 3 hours
at 4◦C. The blocked wells were incubated with 40 µL of sample solution. As detection
antibody biotinylated adalimumab and infliximab (EZ-Link NHS-PEG4-Biotin, Thermo
Fisher Scientific) were used. After an incubation time of 1 hour and three washing steps
with PBST, 20 µL of a 1 µg/ml Streptavidin-HRP (BioLegend) solution were added to
each well for 30 minutes. The final read-out was performed by adding TMB substrate
(Thermo Fisher Scientific) and using a plate reader (Infinite M200, Tecan) to measure the
absorbance at 450 nm.
3.1.3.5 Plasma samples
Plasma samples of 10 inflammatory bowel disease patients under the treatment of adali-
mumab (n=4) and infliximab (n=6) were collected by the Department of Gastroenterology,
Marburg, Germany. Analysis of the collected samples was approved by the ethics com-
mittee of the University Hospital of Marburg and Gießen and carried out according to
standardized laboratory work procedures for infectious materials.
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Table 3.1: Clinical information on plasma samples
Patient ID Sex Age [y] Disease Drug treatment Therapy duration [m]
P1 m 26 UC Infliximab 7
P2 m 20 MC Infliximab 3
P3 f 54 CI Adalimumab 1
P4 f 32 MC Adalimumab 3
P5 m 22 UC Adalimumab 9
P6 m 39 MC Infliximab 8
P7 m 30 MC Infliximab 8
P8 m 57 UC Infliximab 13
P9 m 29 CC Infliximab 86
P10 f 44 UC Adalimumab + MTX 25
MC= Crohn’s disease, UC = ulcerative colitis CI = Colitis indeterminata, CC = Crohn’s
colitis,
MTX = Methotrexate
3.1.4 Results and discussion
3.1.4.1 Assay and array design
The assay was designed to characterize a patient sample by the simultaneous investigation
of three parameters: (i) the type and concentration of free drug, (ii) the presence and
amount of ADAs against different drugs as well as (iii) an estimation of the amount of IgM
within the quantity of all ADA isotypes. The quantification of free drug was necessary for
this test as the detection of ADAs provided valid results only if the drug level was below
a certain concentration - also known as drug tolerance level. Despite the quantification
of ADAs itself, the quantification of anti-drug specific IgMs was further included in order
to distinguish between an IgM-dominated early-stage or an IgG-related late-stage immune
reaction.
As illustrated in figure 3.1 A and B, TNF-α, adalimumab, infliximab, HCA203 (anti-
adalimumab), HCA213 (anti-infliximab) and a serial dilution series of human IgM were
spotted on the microarray surface. After the surface had been blocked, the sample ma-
terial, consisting of drug antibodies (adalimumab or infliximab) and ADAs (against adal-
imumab, infliximab or both), was incubated. Depending on the individual composition
of each sample, adalimumab and infliximab antibodies bound to TNF-α as well as the
74
corresponding surrogate anti-drug antibodies (HCA203 and HCA213). ADAs bound to
either adalimumab or infliximab. In the next step, the sample solution was replaced by a
detection solution which consisted of labeled adalimumab, infliximab and anti-human IgM.
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Figure 3.1: Immunodetection principles and spotting pattern
The three detection principles represented in A consist of a competitive drug
quantification (I), an ADA bridging assay (II) and the detection of IgM ADAs
(III). In B the spotting pattern is pictured, which includes a human IgM
dilution series for the estimation of IgM levels.
The type and concentration of free drug could be determined, considering HCA203 as
binding target for adalimumab, HCA213 as target for infliximab and TNF-α as target
for both. The free drug in the patient sample competed with the fluorescently labeled
drug in the detection solution against the mentioned binding sites, allowing a competitive
quantification.
The amount of ADAs was determined using a bridging format, in which the ADAs in
the sample functioned as a bridge between immobilized and fluorescently labeled drug.
Utilizing the same detection antibody in the competitive quantification strategy as well as
in the bridging format, the calculation of drug and ADA concentrations could be combined
in one step.
By the addition of a labeled anti-human IgM detection antibody, which bound to the IgM-
ADAs forming the bridge as well as the human IgM dilution series, it was further possible
to correlate and calculate the amount of anti-drug specific IgMs.
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3.1.4.2 Microarray preparation
Spotting several binding pairs (TNF-α and infliximab/adalimumab, adalimumab and
HCA203, infliximab and HCA213) on one microarray test field demanded for an optimiza-
tion of our preparation process so that TNF-α could not interfere with adalimumab and
infliximab or vice versa. As depicted in figure 3.2 A, a saturation of the surface with TNF-
α was reached at a concentration of 0.25 µg/ml. Consequently, the amount of interfering
protein, which did not immobilize on the surface, would have been increased if spotting
solutions with a protein concentration above 0.25 µg/ml had been used.
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Figure 3.2: A - Solutions with different infliximab and TNF-α concentrations were
spotted on epoxysilanized glass slides. The immobilized proteins were detected
using fluorescently labeled TNF-α or infliximab.
B - Achieved signal intensities of adalimumab spots after incubation with
fluorescently labeled TNF-α in different test fields. On the ’adalimumab’ test
field only adalimumab was immobilized. On the ’+HCA203’ test field
adalimumab and HCA203 were immobilized. On the ’+TNF’ test field
adalimumab and TNF-α were immobilized. On the ’+HCA203/TNF’ test field
adalimumab, HCA203 and TNF-α were immobilized, but an additional acidic
washing step was performed.
In contrast to the expected concentration dependent immobilization of TNF-α, a hook
effect was observed for the immobilization of infliximab. An explanation for this phe-
nomenon might be described in a model: At the point of complete saturation a monolayer
of antibodies covers the slide surface. Using a protein concentration which is above the
monolayer saturation level, may lead to the buildup of additional antibody layers. Anti-
bodies in the upper layers will preferably bind levitating antigens during incubation. Still,
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the formed immune complexes with antibodies in the upper layers tend to be rinsed in the
final washing step, paradoxically leading to a reduced signal intensity. The likeliness of
layer formation might be dependent on the interaction forces between proteins of the same
kind such as aggregation behavior.
Even though proteins were spotted in concentrations at the saturation level, the interfer-
ence of different binding partners could not be avoided as illustrated in figure 3.2 B. If
either HCA203 or TNF-α was spotted next to adalimumab and no acidic washing step was
included prior to the incubation with labeled TNF-α, the majority of adalimumab recog-
nition sites was occupied leading to a signal intensity decrease of 88.6 or 83.6 %. Including
a final acidic washing step using 1 M glycine buffer (pH 2.6) supplemented with 1 % (v/v)
Tween 20 into the microarray preparation workflow, the formation of interfering immune
complexes could be avoided or dissolved.
3.1.4.3 Assay performance
Detection as well as quantification of adalimumab and infliximab concentrations
Plasma concentrations of adalimumab and infliximab were determined using a competitive
quantification strategy: the free drug antibody in the plasma sample competed against the
fluorescently labeled drug antibody for the available binding sites either on the TNF-α or
the corresponding surrogate anti-drug antibody (HCA203 and HCA213). As the used drugs
bound to TNF-α with a higher affinity (Kd(adalimumab) = 8.6 pM, Kd(infliximab) = 4.2
pM - [17]) than against HCA203 and HCA213 (Kd(HCA203) = 0.15 nM, Kd(HCA213) =
1.8 nM), TNF-α was in favor for the calculation of drug concentrations. However, HCA203
and HCA213 were needed to differentiate which of the two TNF-binding drugs was present
in the sample.
Figure 3.3 A reveals that it was possible to quantify adalimumab in a concentration range
from 0.01 to 4 µg/ml and infliximab in a concentration range from 0.004 to 4 µg/ml. De-
pending on the amount of labeled detection antibody, the dynamic quantification range
could also be shifted towards either higher or lower concentrations.
ADA quantification with bridging format
The entity of all ADAs in a patient sample is an individual collection of antibodies, which
differ in isoform, epitope specificity as well as affinity. For this reason, standardized and
well characterized surrogate anti-drug antibodies - HCA203 and HCA213 - were employed
to determine a calibration curve for the quantification of ADA levels. As seen in figure 3.3
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Figure 3.3: Assay performance
A - Competitive quantification of adalimumab and infliximab (four parameter
logistic curve fit)
B - Quantification of HCA203 and HCA213 in bridging format (log-log fit)
C - Investigation of drug tolerance level at an ADA concentration of 250
ng/ml (four parameter logistic curve fit)
D - Quantification of human IgM via the reference dilution series (linear fit)
B, HCA203 and HCA213 concentrations starting at 10 ng/ml could be quantified, which
complies the FDA industry guideline ’Assay Development and Validation for Immunogenic-
ity Testing of Therapeutic Protein Products’ recommending a test sensitivity of at least
250 - 500 ng/ml.
Investigation of drug tolerance
Quantifying ADAs in patient samples using the chosen bridging format provides the most
valid results if the concentration of free drug is below 0.01 µg/ml. Represented in figure
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3.3 C, the signal intensities for a constant surrogate ADA level at 250 ng/ml decreased
with increasing concentrations of the corresponding drug. At a concentration of 1 µg/ml
and higher, a detection of ADAs is no longer possible. Therefore, the calculation of ADA
levels in patient samples with a free drug concentration above this threshold had to be
interpreted with care - ADAs could be present, yet not detectable in such a sample. For
this reason, it was of importance to collect samples before a new dosage of adalimumab or
infliximab had been administered to the patient.
In order to circumvent ADA quantification interferences with higher drug levels, an acidi-
fication strategy, to dissolve and reassemble drug and ADA immunocomplexes, was tested.
Neither a sample acidification with a 0.2 M glycine buffer (pH 2.6) nor with 0.15 M acetic
acid and a following neutralization using Tris or NaHCO3 (pH 9.0) buffers resulted in about
80 % lower signal intensities compared to the unacidified samples (data not shown). As
the pH adjustment from around 3 to 7 - 8 was monitored, an insufficient neutralization
capacity of the used buffers could be denied. By the addition of 30 µl neutralizing buffer
to the 70 µl of incubated sample solution, the volume was increased by 42 %. This volume
increase leads to a reduced concentration of analytes, which might be the most plausible
explanation for the decreased ADA signal intensities. Still, the reduced concentration was
not expected to result in a signal intensity reduction of 80 % and should have also been
partly compensated by the amount of ADAs, which had been made accessible by this. An
optimization in this regard would be necessary. However, up until now no acidification
step was included into the method stream.
Estimation of IgM level
The IgM calibration curve in figure 3.3 D was derived from the spotted serial dilution
series and used as quantification reference. As a precise calibration with target bound IgM
antibody could not be carried out, it could only provide an estimation of the actual IgM
concentration
3.1.4.4 Analysis of clinical samples
Samples of ten patients under a current adalimumab or infliximab treatment were analyzed
(see table 3.1). In contrast, the plasma samples of five healthy individuals were pooled and
used as negative control.
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Determination of adalimumab and infliximab plasma concentrations
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1 – TNF: quantification of adalimumab/infliximab
2 – Adalimumab: detection of adalimumab ADAs
3 – HCA203: detection of adalimumab
4 – Infliximab: detection of infliximab ADAs
5 – HCA213: detection of infliximab
1
Figure 3.4: Raw fluorescence images of clinical samples
According to the scheme in figure 3.1 B, the test field consisted of five relevant
areas: Field 1 consisted of six TNF-α spots. By this, the amount of present
anti-TNF-α drugs could be measured in a competitive fashion - high drug
concentration, low signal intensity. In combination with field 3 and 5
(surrogate anti-adalimumab /-infliximab antibodies), it was possible to
determine which drug was present e.g. low HCA203 intensity, high
adalimumab concentration. The spotted drugs in field 2 and 4 indicated
whether ADA were present or not (bridging format)
1st Row : negative control, P5, P7
2nd row : P3
3rd row : P1, P4
(from left to right)
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In figure 3.4 the acquired raw images of different patient samples are represented. The
corresponding test field layout was illustrated in figure 3.1 B. Considering TNF-α (field
1), anti-adalimumab antibody (field 3) and anti-infliximab antibody (field 5) spots, it was
already possible to see whether a patient was under treatment and which drug he/she
received. Taking adalimumab (field 2) as well as infliximab (field 4) into account, it was
further possible to recognize if ADA were present or not.
Calculating with an average weight of 70 kg and a total blood volume of 5 liters, drug
concentrations were expected to be around 10 µg/ml in the case of adalimumab (50 mg
dosage) or 70 µg/ml in the case of infliximab (dosage recommendation: 5 mg/kg) directly
after administration. However, it should be taken into account that the drug titer of
patients under continuous treatment might still be increased before a new dosage is given,
depending on the individual elimination rate and injection intervals.
With a closer look at the measured drug concentrations in figure 3.5 A, it was possible to
stratify and confirm whether a patient had been under treatment with adalimumab (P4,
P5, P10) or infliximab (P2, P6, P7, P8). Furthermore, drug titers were found to be in the
expected range, except for patient P5. Apart from the regular schedule, this patient was
treated on a weekly basis with adalimumab resulting in an elevated plasma concentration
of 22.81 µg/ml.
The determined drug concentrations of patient samples were also in good accordance with
results derived from ELISA experiments, as seen in figure 3.5 B.
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Figure 3.5: Analysis of clinical samples II
A - Measured adalimumab and infliximab concentrations in each patient
sample
B - Correlation of measured drug concentrations; microarray results vs.
ELISA results
C - ADA levels measured in each patient sample
D - IgM-associated ADA levels measured in each patient sample
With regard to an appropriate evaluation of ADA titers with the developed method, it
was necessary that the sample contained no interfering amounts of free drug. Even though
samples were taken prior to a new injection, seven samples featured drug concentrations
above the critical drug tolerance level of 1 µg/ml. As a matter of fact, a precise quantifica-
tion of ADAs could only be ensured for P1, P3 and P9. In comparison with other methods
(ELISA, ECL) a drug tolerance of 1 µg/ml represents a regular level.
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Determination and explanation of anti-adalimumab and anti-infliximab plasma concentra-
tions
The measured adalimumab and infliximab ADA concentrations for each patient sample are
summarized in figure 3.5 C. Calculated as the upper 95th percentile of five negative control
samples, a cut-point value of 3.2 ng/mL was determined for anti-adalimumab and 3.58
ng/mL in the case of anti-infliximab antibody concentrations. Concentrations above this
level were considered as ADA positive as long as the free drug concentration was below the
drug tolerance level. If the free drug concentration was above the drug tolerance level of 1
µg/ml, it had to be assumed that ADAs might still be present, yet remained undetectable.
Regarding the samples from the 4 patients under adalimumab treatment (P3, P4, P5 and
P10), 2 patients were classified as ADA positive. The highest anti-adalimumab concen-
tration of 6.0 ± 0.5 ng/ml was found in patient P3, who received a single adalimumab
injection prior to sampling. Similar to a vaccination process, a time-dependent immune
response with higher ADA levels in patients under a longer lasting adalimumab therapy
were to be expected . Unfortunately, a correlation of the therapy duration and the resulting
anti-adalimumab concentration could not be made as the free drug levels of patient P4, P5
and P10 exceeded the drug tolerance level.
In contrast to anti-adalimumab antibodies, which were only found in patients under adal-
imumab treatment, anti-infliximab antibodies could also be detected in patients treated
with adalimumab. Moreover, the infliximab ADA levels exhibited the highest concentra-
tions in the samples of patients P3 and P4 (treated with adalimumab) amongst all ADA
positive samples. An earlier treatment with infliximab could not be confirmed in these
cases, leading to the assumption that these patients acquired an associated immune re-
sponse against adalimumab as well as infliximab. It is known that patients who already
acquired an immunogenicity against infliximab were also prone to develop antibodies to
adalimumab and vice versa [18–20]. The detected ADAs remained drug specific and a
cross-immunogenicity against both monoclonal antibodies based on the treatment with
just one had not been described so far [21,22].
Up until now, the method at hand allowed a precise quantification of ADAs. In future,
more samples need to be analyzed to deduce clinical conclusions from the calculated ADA
levels. Thus, a better and more precise understanding of how to differentiate between
ADA positive patients developing a therapy resistance and the ones who do not can be
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generated. An approach to gain more information here, would be the specific detection
of neutralizing ADAs in addition to the overall amount of ADAs. This could be accom-
plished by an immobilization of the Fab fragment or an orientated immobilization of the
therapeutic antibody.
Quantification of IgM ADAs
The utilized and above mentioned ADA bridging format is a convenient immunoassay to
quantify ADAs, no matter which isotype. This is particularly useful because in a compa-
rable setup which would consist of the immobilized drug, bound ADAs and an anti-human
detection antibody, one would not be able to quantify the ADAs which are of the same
isotype subclass as the humanized monoclonal drug antibody - usually IgG1. Apart from
the information whether ADAs are present in a sample or not, a discrimination of the
involved antibody isotypes would be a desirable feature.
According to the scheme III in figure 3.1 A, the detection of IgM-associated ADAs was
included into our multiplexed assay. The determined IgM concentrations represented in
figure 3.5 D could only provide an information on the degree of IgM involvement in the
drug-specific immune response. With an elevated IgM concentration of 50 ± 5.5 ng/mL
detected in the negative control sample, it was difficult to assess the calculated concentra-
tions as absolute values. A proper validation with additional IgM negative samples would
be needed here. Nevertheless, comparing the IgM levels of each patient sample in which
ADAs could already be detected, an IgM involvement was observed for P3 and P1 speak-
ing for an immune response at an early stage. Patient P4 with the highest anti-infliximab
antibody level did not show any IgM involvement which gave reason for an IgG-dominated
immune response. Observing the highest IgM levels in the samples of patient P6 and P10,
lead to the assumption that these patients were just about to acquire a drug-related im-
mune response. Further experiments in order to monitor a time-related ADA development
of individual patients are under consideration.
3.1.5 Conclusion
A comprehensive therapeutic drug monitoring of patients under adalimumab or infliximab
treatment demands for the investigation of several parameters such as the drug plasma
concentration as well as the occurrence and type of ADAs. Moreover, the drug plasma
concentration is not only relevant from a pharmacological point of view, but also for the
biological performance of the ADA assay (free drug tolerance). In this work, we combined
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these individual assays in one protein microarray-based test. In experiments with clinical
patient samples (n=10) the applicability of this test could be demonstrated and revealed
that ADAs could be detected in 40 % of the patients under treatment. Also, a cross-
immunogenicity against both drugs, adalimumab and infliximab, was observed in two cases.
The information about an acquired or developing therapy resistance is of high value for the
responsible clinician in order to select the future therapy options for the individual patient.
Therefore, the microarray platform might be of special interest as it is not restricted to
the analysis of adalimumab, infliximab and corresponding ADAs but can also easily be
upgraded by many other drug candidates, which might be beneficial especially with regard
to the development of biosimilars.
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3.2 Quantification in plasma of the protein drugs
infliximab and adalimumab as well as the patients’
corresponding immune response using a
smartphone-attachable blood glucose meter
3.2.1 Abstract
Therapeutic drug monitoring is an essential component of the treatment of rheumatic pa-
tients. In a proof-of-concept study, we describe the use of a blood glucose meter read-out
for the quantification of the plasma concentration of the anti tumor necrosis factor alpha
(TNF-α) antibodies adalimumab and infliximab. Employing a competitive assay strategy
based on the enzymatic activity of invertase - hydrolyzing sucrose into glucose and fructose
- plasma antibody concentrations could be measured quantitatively in a range of 0.01 to
47 µg/ml within 50 minutes. Furthermore, a related assay allowed the identification of
anti-drug antibodies (ADAs) that may result from a patient’s immune response to treat-
ment. ADA concentrations of 1.6 to 1000 ng/ml could be detected within three hours,
exhibiting a free drug tolerance of 1 µg/ml. The method was used to characterize clinical
samples from inflammatory bowel disease patients to demonstrate its applicability. Uti-
lizing a smartphone attachable blood glucose meter, protein drug concentrations could be
determined remotely and transferred to relevant sites by cellular phone.
3.2.2 Introduction
Monitoring of therapeutic drug concentrations is a key component of a patient-specific
treatment optimization. In order to achieve the most effective clinical response, a pa-
tient’s plasma drug level should be adjusted to a certain concentration range - commonly
known as the therapeutic window. This applies to small molecules as well as biological
drugs. Especially patients with decreased drug clearance capacity could benefit from pro-
longed treatment intervals; this would also prevent over-dosing. For protein drugs, also
the cost factor is particularly high. Therapeutic drug monitoring is therefore cost-effective
as demonstrated for the therapeutic antibody adalimumab, for example [1, 2]. Further-
more, the administration of protein drugs could trigger the immune system similar to a
vaccination process, leading to the generation of anti-drug antibodies (ADAs) [3]. As a con-
sequence, ADAs can cause therapy resistance, especially if neutralizing antibodies against
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the active drug site are formed. It was shown that even drug concentrations below the
effective dose can provoke ADA formation [4]. Long lasting and expensive anti-rheumatic
therapies with monoclonal antibodies against tumor necrosis factor alpha (TNF-α) tend
to loose clinical response effectiveness over time [5]. Their monitoring should therefore not
only include the correct adjustment of the administered dose, but also the determination
of ADA levels.
Small molecules are typically quantified in blood by employing liquid chromatography
coupled to mass spectrometry. This process is also used for the precise quantification of
specific proteins, yet it is quite laborious and cost-intensive taking into account the sample
preprocessing and the required instrumentation. In contrast, biological drugs, such as an-
tibodies, can be analyzed with immunoassay techniques, which do not necessarily require
an extensive infrastructure. Here, we demonstrate that the plasma concentration of the
therapeutic antibodies adalimumab and infliximab as well as that of ADAs against these
protein drugs can be measured with a simple and portable setup consisting of antigen-
coated magnetic beads, an invertase-labeled therapeutic antibody, a sucrose solution and
a blood glucose meter. The invertase is used as reporter enzyme. In contrast to classical
reporter enzymes, such as horseradish peroxidase and alkaline phosphatase, which produce
colored or chemiluminescent molecules, invertase hydrolyses sucrose into glucose and fruc-
tose. Thus, a blood glucose meter can be used as a read-out tool for quantifying the amount
of glucose, which correlates with the amount of the protein of interest. Similar approaches
have been used for the quantification of pathogenic bacteria, protein biomarkers, small
molecules as well as mercury [6–12]. Coupling the assay to commercial instrumentation
and related software permits a measurement even in remote locations and a direct transfer
of the generated data via a cellular phone.
3.2.3 Materials and Methods
3.2.3.1 Coating magnetic beads with TNF-α
N-hydroxysuccinimide (NHS)-activated magnetic beads (Thermo Fisher Scientific) were
coated with TNF-α (ATGen) according to the manufacture’s protocol. A volume of 300
µl bead suspension (bead concentration 10 mg/ml) was activated with 1 ml ice-cold 1 mM
HCl and incubated with 2 mg TNF-α in 500 µl 0.1 M NaHCO3, pH 9.0, for 12 hours at
4◦C. The TNF-α-coated beads were washed three times in PBST (PBS supplemented with
0.05 % Tween 20 (Sigma-Aldrich)). Beads were stored in PBST containing 0.05 % sodium
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azide (Sigma-Aldrich) at 4◦C. Measurements of the coupling efficiency via a BCA assay
(Thermo Fisher Scientific) revealed a TNF-α amount of 20 µg/mg of bead.
3.2.3.2 Coating magnetic beads with infliximab or adalimumab
According to the manufacture’s protocol, infliximab (Remicade, MSD Sharp & Dohme)
or adalimumab (Humira, AbbVie.) were dissolved in 500 µl PBS at a concentration of 4
mg/ml. The solution was added to 300 µl bead suspension of protein-A/G coated beads
(bead concentration 10 mg/ml; PureProteome Protein A/G Mix Magnetic beads, Merck).
After a 12 hour incubation at 4◦C, the beads were washed with PBST. Subsequently, bound
antibodies were covalently cross-linked to the protein-A/G using bis(sulfosuccinimidyl)-
suberate (BS3, Thermo Fisher Scientific). Measurements of the coupling efficiency via
a BCA assay (Thermo Fisher Scientific) revealed an adalimumab amount of 182 µg per
milligram of bead and an infliximab amount of 176 µg/mg.
3.2.3.3 Elution and recycling of magnetic beads
It was possible to elute infliximab or adalimumab molecules from the magnetic particles
with covalently bound TNF-α and reuse the beads for further measurements. Prior to
elution, the magnetic beads were washed three times with PBST. They were then resus-
pended in 1 ml of 1 M glycine, pH 2.6, and incubated for 15 min at 56◦C at continuous
shaking. After this, the beads were washed five times with PBST and stored in PBST
containing 0.05 % sodium azide (Sigma-Aldrich) at 4◦C.
3.2.3.4 Invertase-conjugation of infliximab or adalimumab using sodium periodate
For oxidizing the glycosylation moiety of invertase, 36 mg of S. cerevisiae invertase (grade
V, Sigma-Aldrich) were dissolved in 3.6 ml 0.1 M sodium acetate, pH 4.5, and 3.88 mg
of sodium periodate (NaIO4, Sigma-Aldrich). The reaction mix was protected from light
and incubated at room temperature. After 2 hours, the solution was filtered through a
0.22 µm pre-syringe filter and dialyzed with 0.1 M sodium acetate buffer, pH 4.5, using
centrifugal filter units (Amicon, MWCO 10 kDa, Merck Millipore). An amount of 6 mg
infliximab (Remicade, MSD Sharp & Dohme) or adalimumab (Humira, AbbVie) dissolved
in 0.5 ml 1 M NaHCO3, pH 9.0, was added to the activated invertase. After an overnight
incubation at 4◦C, NaBH3CN was added to a final concentration of 50 mM in order to
reduce imines, followed by an additional incubation at room temperature for 30 min.
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Finally, the invertase-antibody conjugate was purified by size-exclusion chromatography
(Superdex 200 column, ÄKTA Explorer, mobile phase: PBS).
3.2.3.5 Invertase-conjugation of infliximab or adalimumab using glutaraldehyde
Six milligram infliximab or adalimumab and 36 mg invertase were dissolved in 4.2 ml
0.1 M NaHCO3 buffer, pH 9.0. Glutaraldehyde (Sigma-Aldrich) was added to a final
concentration of 0.25 % (w/v). The reaction mixture was incubated at room temperature
for 20 minutes and purified by size-exclusion chromatography as described above.
3.2.3.6 Activity measurement of the invertase-infliximab conjugate
In order to investigate the pH and temperature dependence of the hydrolytic activity of
the invertase-antibody conjugates, 1 µg invertase-conjugate was dissolved in a substrate
solution containing 0.5 M sucrose either in 0.1 M sodium acetate at a pH ranging from 3.5
to 5.5, or in sodium phosphate at pH 6 to 8. Furthermore, the incubation temperature was
varied between 20◦C and 60◦C. iBGstar blood glucose test stripes and the iBGstar blood
glucose meter (Sanofi) were used for quantifying the amount of glucose as recommended
by the manufacturer.
For an analysis of the invertase-infliximab conjugate, the conjugate was serially five-fold
diluted in PBS in a concentration range from 4.2 mg/ml to 10.7 ng/ml. A volume of 20 µl
of each concentration was added to 0.2 mg of TNF-α-coated magnetic beads and incubated
at room temperature for 1 hour. After three washing steps with PBST, the beads were
resuspended in the substrate solution (0.5 M sucrose in 0.1 M sodium acetate, pH 4.5) and
incubated at 40◦C. The invertase activity was detected with the iBGstar system. A volume
of 0.8 µl was added to a test stripe. Following the manufacturer’s recommendations, we
aimed at reaching a signal equivalent to a glucose concentration of around 100 mg/dl as it
represents the most accurate region for signal intensity measurements.
3.2.3.7 Competitive quantification of infliximab or adalimumab
A serial dilution of infliximab or adalimumab was prepared in pure plasma (pooled plasma
of 5 healthy individuals). Ten microliter of each dilution was mixed with 10 µl PBST
containing 1.5 µg/ml infliximab- or adalimumab-invertase conjugate. The mixture was
then added to 0.2 mg of TNF-α-coated magnetic beads and incubated for 1 hour at room
temperature. After three washing steps with PBST, the beads were resuspended in 0.5 M
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sucrose in 0.1 M sodium acetate, pH 4.5, and incubated at 40◦C for 50 minutes. BGstar
blood glucose test stripes and the smartphone attachable iBGstar blood glucose meter
were used as read-out instrument to quantify the amount of glucose. Experiments were
repeated three times, generating a triplicate of individual measurement points. A four-
parameter logistic curve fit was performed to visualize the dynamic quantification range.
For calibration purposes, a semilog line fit (logarithmic x-axis and linear y-axis) was applied
to data points in the dynamic quantification range using GraphPad Prism 7.
3.2.3.8 Quantification of anti-drug antibodies (bridging format assay)
Five-fold serial dilutions of anti-adalimumab and anti-infliximab antibodies (HCA203,
HCA213; AbD Serotec - Bio-Rad Laboratories) were prepared in pure plasma (pooled
plasma of 5 healthy individuals). The samples were diluted 1:10 with PBST and 20 µl of
this solution were added to 0.4 mg of adalimumab- or infliximab-coated beads. After an
incubation for 3 hours at 4◦C and three washing steps with PBST, 20 µl of adalimumab-
or infliximab-invertase conjugate at a concentration of 1 µg/ml in PBST was added to the
beads for 1 hour at room temperature. Finally, the beads were washed three times using
PBST, resuspended in the substrate solution (0.5 M sucrose in 0.1 M sodium acetate, pH
4.5) and incubated at 40◦C for 3 hours. The amount of glucose was measured as described
above.
3.2.3.9 Drug tolerance
Plasma samples were spiked with anti-infliximab antibody HCA213 at a constant concen-
tration of 200 ng/ml and different infliximab concentrations from 1 mg/ml down to 10
ng/ml. Samples were then further processed as already described for the quantification of
anti-infliximab antibodies
3.2.3.10 ELISA
ELISA experiments were used as reference for the competitive quantification of infliximab
and the comparison of the drug tolerance of the anti-infliximab antibody assay. 96-well
microtiter plate (Maxisorb, Nunc) were coated by adding 5 µg/ml of TNF-α or infliximab
in 50 µl PBST and incubated overnight at 4◦C. The following day, the protein solution in
the wells was discarded and each well was blocked with 100 µl of 5 % (w/v) skimmed milk
for 3 hours at 4◦C. Test solutions were prepared as described above. Instead of invertase-
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conjugated infliximab, biotinylated infliximab (EZ-Link NHS-PEG4-Biotin, Thermo Fisher
Scientific) was used. After an incubation time of 1 or 3 hours and three washing steps with
PBST, 20 µl of a 1 µg/ml streptavidin-horseradish peroxidase (BioLegend) solution were
added to each well. After 30 minutes at room temperature, the read-out was performed by
adding TMB chromogenic substrate (3,3’,5,5’-tetramethylbenzidine, Thermo Fisher Scien-
tific) and a plate reader (Infinite M200, Tecan) to measure the absorbance at 450 nm.
3.2.3.11 Plasma samples
Plasma samples of 10 inflammatory bowel disease patients treated with adalimumab (n=4)
or infliximab (n=6) were collected at the Department of Gastroenterology and Endocrinol-
ogy, University Hospital, Philipps-University Marburg, Germany (see table 3.2). All pa-
tients had given written informed consent. Analysis of the collected samples was approved
by the ethics committee of the University Hospital of Marburg and Gießen and carried out
according to standardized laboratory work procedures for potentially infectious materials.
Table 3.2: Clinical characteristics of the patients, whose plasma samples were analyzed
Patient ID Sex Age [y] Disease Drug treatment Therapy duration [m]
P1 m 26 UC Infliximab 7
P2 m 20 MC Infliximab 3
P3 f 54 CI Adalimumab 1
P4 f 32 MC Adalimumab 3
P5 m 22 UC Adalimumab 9
P6 m 39 MC Infliximab 8
P7 m 30 MC Infliximab 8
P8 m 57 UC Infliximab 13
P9 m 29 CC Infliximab 86
P10 f 44 UC Adalimumab + MTX 25
Clinical characteristics of the patients, whose plasma samples were analyzed.
M= male; f = female; MC = Crohn’s disease; UC = ulcerative colitis; CI = Colitis
indeterminata; CC = Crohn’s colitis; MTX = Methotrexate.
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3.2.4 Results and discussion
As illustrated in Figure 3.6, we used a competitive strategy for the quantification of adal-
imumab as well as infliximab in plasma. A defined amount of invertase-conjugated inflix-
imab or adalimumab, respectively, was mixed with a patient’s plasma sample and added to
magnetic beads coated with TNF-α. Depending on the molar ratio of free and invertase-
conjugated antibody in the sample, more or less invertase-conjugated antibody bound to
the TNF-α on the magnetic beads. The amount of TNF-α-bound invertase determined
how much glucose was generated once the sucrose solution was added. The glucose level
was measured with a commercial read-out system. The glucose acts as a surrogate for
the amount of protein-drug as it correlates inversely with the infliximab or adalimumab
concentration in the plasma sample. The magnetic beads simplify the handling during the
entire analysis process as they - and thereby the analytes bound to them - can be collected
quickly and easily after each washing step.
Figure 2 – Competitive antibody quantification
A plasma sample was mixed with the detection solution and TNF-ɑ-coated magnetic particles. During incubation, free antibody
from the plasma sample and invertase-labeled antibody from the detection solution compete against the available TNF-ɑ
binding sites on the magnetic beads. A substrate sucrose solution was added and the bead-bound invertase hydrolyzes the
sucrose into fructose and glucose. Using a blood glucose meter (iBGstar, Sanofi), the glucose concentration, which correlates
with the amount of antibody in the sample, can be measured.
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Fig re 3.6: Schematic representation of the competitive quantification process
for the detection of infliximab or a alimumab.
A plasma sample is mixed with TNF-α-coated magnetic particles and
invertase-conjugated drug antibody. During incubation, free therapeutic
antibody (infliximab or adalimumab) of the plasma sample and the
invertase-conjugated antibody of the detection solution compete for the
available TNF-α binding sites on the magnetic beads. Subsequently, a sucrose
solution is added as a substrate and the bead-bound invertase hydrolyzes the
sucrose into fructose and glucose. Using a blood glucose meter, the glucose
concentration is measured, which inversely correlates with the amount of
antibody in the plasma sample.
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3.2.4.1 Optimization of assay conditions
Using a blood glucose meter as read-out instrument requires a glucose concentration in the
range of 20 to 600 mg/dl. Since it was our aim to perform measurements quickly, several
experimental conditions were studied and optimized in order to enhance the enzymatic
hydrolysis of sucrose into glucose and fructose and thus the speed of the measurement.
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Figure 3.7: Activity of the invertase-antibody conjugates.
(A) Comparison of invertase activity of the free enzyme (native) to that of the
conjugate after coupling to infliximab by sodium periodate (NaIO4) or
glutaraldehyde activation. (B) The invertase activity was determined at
different pH. (C) Enzyme kinetics at different incubation temperatures. (D)
Quantification of the activity of the infliximab-invertase conjugate at different
concentrations. Each value in the four panels is the mean of two individually
repeated experiments with two measurements per experiment sample; the
standard deviation was calculated based on all four measured values.
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Antibody-invertase conjugation:
The covalent coupling of the antibody to the invertase may impact the invertase activity.
Therefore, conditions had to be chosen carefully not to affect the enzymatic activity by
this conjugation but still to produce sufficient conjugate yield. Two coupling procedures
were tested, using either glutaraldehyde or sodium periodate for invertase activation. The
enzyme activities of the resulting, purified conjugates were compared with untreated in-
vertase (Figure 3.7 A). A higher yield of antibody-invertase conjugate was achieved with
0.25% glutaraldehyde (data not shown), yet the invertase activity of the respective conju-
gate was reduced by 67.7% compared to untreated invertase. In contrast, activity of the
conjugate decreased by only 14.2% if sodium periodate was used as coupling activator.
Incubation pH and temperature:
The activity of invertase-antibody conjugates was analyzed at different pH. The enzyme ex-
hibited its highest activity at pH 4.5 (Figure 3.7 B). Not surprisingly, activity also changed
with temperature (Figure 3.7 C). The findings were in good agreement with results for
unconjugated invertase [6–8]. Even though an incubation temperature of 60◦C yielded the
highest hydrolysis rate, we chose a temperature of 40◦C for all subsequent experiments so
as to reduce any kinetic variation in glucose generation over time, which is indicated by
the increasing standard variations at 50◦C and 60◦C. Protein denaturation is substantially
slower and basically negligible at 40◦C. Also, working with a small volume of 20 µl, evap-
oration might have an influence on the glucose concentration during incubation. However,
no significant effect was found at 40◦C.
Sucrose/glucose concentration:
The invertase’s enzymatic activity is dependent on the sucrose concentration. Similar to
reports of other groups [13], a maximal generation of glucose was achieved at a sucrose
concentration between 0.25 M and 1 M (data not shown). It should be mentioned that the
incubation time could not be reduced by the addition of glucose to the sucrose solution,
thereby starting the measurement at a glucose concentration that is better for detection,
because glucose serves as a catabolic inhibitor of the invertase activity [13]. In summary,
using sodium periodate for the antibody-invertase conjugation, a substrate solution with
0.5 M sucrose and performing the hydrolysis reaction at pH 4.5, in a volume of 20 µl and
at a temperature of 40◦C were found to be the most appropriate assay conditions.
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3.2.4.2 Determining the range of quantification with invertase-conjugated
infliximab
For performing competitive quantification analyses, it was important to determine the
range of invertase-labeled infliximab concentration that could be analyzed quantitatively.
The reaction was found to be linear across about five orders of magnitude ranging from
0.05 to 5,000 µg/ml (Figure 3.7 D). Also, concentrations above 5,000 µg/ml would be
detectable as no saturation of the TNF-α binding sites on the beads was observed. If
longer incubation periods were employed, also lower concentrations could be covered. Yet,
for the intended purpose, there was no need to aim at plasma concentrations below 0.05
.µg/ml infliximab.
3.2.4.3 Competitive quantification of adalimumab and infliximab
The competitive strategy allowed an adjustment of the dynamic quantification range by
varying the amount of added invertase-conjugated infliximab. A concentration of 30 µg/ml
invertase-conjugated infliximab resulted in a detection limit at 12 µg/ml (Figure 3.8 A).
In contrast, a concentration of 1.5 µg/ml invertase-conjugated infliximab yielded a dy-
namic range between 0.7 and 46 µg/ml. Apart from affecting the detectable concentration
range, a closer look at the molar ratios of free and invertase-conjugated antibody was in-
teresting. One would assume that a 1:1 molar ratio represents the half-maximal inhibitory
concentration (IC50), if free and invertase-conjugated antibody feature the same affinity.
However, instead of the IC50, the lower limit of detection marked the point at which a 1:1
equilibrium of free and invertase-conjugated antibody was reached. Since there is no full
saturation of all the TNF-α binding sites on the beads with infliximab (Figure 3.7 D), a
molar excess of free infliximab is needed to displace bound invertase-conjugated antibody.
As an adalimumab or infliximab plasma concentration of at least 5 µg/ml is necessary for
an effective therapeutic response [14], we adjusted our quantification range accordingly to
0.01 to 47 µg/ml (Figure 3.8 B). The measured and plotted data points were fitted as
a semilog line within the dynamic quantification range (0.01 - 46.8 µg/ml) and used as
calibration curves for the quantification of adalimumab and infliximab in plasma.
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Figure 3.8: Investigating effectors of the competitive adalimumab/infliximab
quantification.
(A) The dynamic quantification range is dependent on the ratio of free and
invertase-conjugated therapeutic antibody after mixing the patient sample and
the detection solution. The analysis strategy allows an adjustment of this
range by varying the amount of the invertase-infliximab conjugate. Results are
shown for two concentrations; the graphs were produced with a four-parameter
logistic curve fit. (B) Generation of calibration curves for the quantification of
adalimumab and infliximab by spiking known concentrations into plasma
samples. (C) Correlation of results achieved by performing the experiments in
PBS buffer or patient plasma. (D) Correlation of values obtained by
employing for quantification ELISA and the glucose detection process.
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3.2.4.4 Matrix effects and comparison with ELISA quantification
In order to demonstrate the applicability of the method, experiments regarding matrix
effects were carried out. Signals obtained with glucose detection in PBS buffer correlated
very well with data generated in plasma samples (Figure 3.8 C). This proved that neither
any glucose nor TNF-α in plasma samples disturbed the quantification of the therapeutic
antibodies. In addition, results were confirmed with ELISA as a reference method that
still represents a gold standard in the quantification of protein concentrations. The process
resulting in the read-out of glucose levels provided results, which were in agreement with
data obtained in ELISA experiments (Figure 3.8 D).
3.2.4.5 Quantification of anti-adalimumab or anti-infliximab antibodies
Apart from the quantification of the therapeutic antibody concentration itself, an appro-
priate therapy monitoring also incorporates the quantification of ADAs. Their occurrence,
especially of neutralizing ADAs, is a common problem limiting the effectiveness of therapies
with biologicals. In order to investigate whether the detection of ADAs is possible using
the glucose read-out, we modified the competitive quantification strategy into a bridging
format (Figure 3.9). We prepared infliximab- and adalimumab-coated magnetic beads,
incubated plasma samples containing surrogate anti-adalimumab and anti-infliximab an-
tibodies and finally added the corresponding invertase-conjugated drug antibody. The
used surrogate ADAs were designed to bind either the antibody in complex with TNF-α
(HCA203, anti-adalimumab, binding type 3, non-inhibitory) or the antibody’s paratope
(HCA213, anti-infliximab, binding type 1, inhibitory and neutralizing). A concentration
dependent detection of HCA203 and HCA213 was achieved (Figure 3.10 A). Employing
a semilog line fit, a quantification performance across nearly three orders of magnitude
from 1.6 to 1,000 ng/ml could be demonstrated. Also, similar slope values of the trend
line indicated an equal binding kinetics of the paratope-specific and the anti-drug/TNF-α
complex antibody.
101
Fe
Y
+
Magnetic bead
Anti-drug antibody
Invertase
Infliximab/Adalimumab
V
o
o
o
X
Sucrose
Patient 
sample
o
o
o
o
o
o
Y
Fe
Y
Y InvY
+
Fe
Y
Y
+
Y
Fe#
Y 
+#
Magnetic bead 
Anti-drug antibody 
Invertase 
Infliximab/Adalimumab 
V 
o"
o"
o"
X"
Sucrose 
Patient  
sample 
o#
o#
o#
o#
o#
o#
Y
Fe#
Y
Y Inv#Y
+#
Fe#
Y
Y
Inv#
+#
Y
Fe#
Y 
+#
Magnetic bead 
Anti-drug antibody 
Invertase 
Infliximab/Adalimumab 
V 
o"
o"
o"
X"
Sucrose 
Patient  
sample 
o#
o#
o#
o#
o#
o#
Y
Fe#
Y
Y
 Inv#
Y
+#
Fe#
Y
Y
Inv#
+#
Y
Fe#
Y 
+#
Magnetic bead 
Anti-drug antibody 
Invertase 
Infliximab/Adalimumab 
V 
o"
o"
o"
X"
Sucrose 
Patient  
sample 
o#
o#
o#
o#
o#
o#
Y
Fe#
Y
Y Inv#Y
+#
Fe#
Y
Y
Inv#
+#
Y
Fe#
Y 
+#
Magnetic bead 
Anti-drug antibody 
Invertase 
Infliximab/Adalimumab 
V 
o"
o"
o"
X"
Sucrose 
Patient  
sample 
o#
o#
o#
o#
o#
o#
Y
Fe#
Y
Y Inv#Y
+#
Fe#
Y
Y
Inv#
+#
Y
Figure 4 – Anti-drug antibody quantification (bridging format)
A plasma sample with spiked anti-drug antibodies was added to adalimumab or infliximab-coated magnetic particles. Bound
anti-drug antibodies could then be detected with the corresponding invertase-labeled antibody.
Figure 2 – Competitive antibody quantification
A plasma sample was mixed with the detection solution and TNF-ɑ-coated magnetic particles. During incubation, free antibody
from the plasma sample and invertase-labeled antibody from the detection solution compete against the available TNF-ɑ
binding sites on the magnetic beads. A substrate sucrose solution was added and the bead-bound invertase hydrolyzes the
sucrose into fructose and glucose. Using a blood glucose meter (iBGstar, Sanofi), the glucose concentration, which correlates
with the amount of antibody in the sample, can be measured.
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ure 3.9: Sche atic presentatio of the process of anti-drug antibody (ADA)
quantification (bridging format).
A plasma sample with anti-drug antibodies is added to adalimumab- or
infliximab-coated magnetic beads. Bound anti-drug antibodies are
subsequently detected with the corresponding invertase-conjugated antibody,
upon which sucrose hydrolysis is used as a means for detection and
quantification.
Compared to the competitive quantification of drug antibodies, an increased back-
ground was noticed in the bridging format. To investigate whether this effect was due
to the utilization of protein A/G-coated magnetic particles, as the invertase-conjugated
antibodies could also bind to both the ADAs and free protein-A/G sites on the mag-
netic particles, infliximab and adalimumab were immobilized on NHS-magnetic particles.
Yet, the same background intensity was obtained. It is possible that the drug antibod-
ies also form bridges with TNF-α. However, an elevated plasma concentration of TNF-
α in rheumatic patients, which is reported to reach up to 1.2 ng/ml, seems to be too
low to result in any pronounced background [15]. The slightly increased background
signal is probably due to unspecific binding. According to the FDA guidance for in-
dustry ’Assay Development and Validation for Immunogenicity Testing of Therapeutic
Protein Products’ (https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf),
a suitable ADA assay should exhibit a sensitivity of at least of 250 to 500 ng/ml. This
requirement is met with the antibodies in this proof-of-concept study.
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Figure 3.10: Quantification of anti-drug antibodies and investigation of the drug
tolerance value.
(A) Dilution series of surrogate anti-drug antibodies were prepared in
plasma. Each sample was processed and measured according to the bridging
format illustrated in figure 3.9. (B) A serial dilution of infliximab with a
constant concentration of 200 ng/ml HCA213 was prepared in plasma. The
amount of HCA213, which was able to bind to the solid support -
infliximab-coated magnetic particles or ELISA microtiter plate - was
measured using the bridging format either with invertase- or
biotin-conjugated infliximab. Each data point represents the mean value of
two repeated experiments with two measurements per sample. The standard
deviation was calculated from the four measurement values.
3.2.4.6 Free drug tolerance
While the quantification of ADAs could be realized technically, further physiological and
biological conditions of the patient sample needed to be taken into account, too. It is not
certain that one is able to quantify ADAs even if they are present. The reason for this
is the fact that a patient might exhibit a high therapeutic antibody titer due to a recent
administration or a slow metabolism. ADAs will then bind to the drug molecules making
it difficult to detect the ADAs as the immuno-detection is also based on the interaction
of the ADAs and the therapeutic drug, the latter immobilized on the detection platform.
The higher the amount of free drug, the less ADAs will be available for detection. The
free drug tolerance indicates at which concentration of free therapeutic antibody the ADA
assay would be disturbed.
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In order to determine the tolerance value, plasma was spiked with infliximab at different
concentrations and 200 ng/ml of HCA213. Figure 3.10 B shows that both methods, glucose
detection and ELISA, tolerated an infliximab concentration of 0.1 µg/ml. However, the
addition of infliximab had a major impact on the standard deviation of the signals even at
low concentrations.
It is possible to increase assay sensitivity as well as the tolerance to free drug, if an acid dis-
sociation that dissolves immuno-complexes and a subsequent neutralizing step is included
in the workflow [16]. Accordingly, we performed such dissociation with 300 mM acetic acid.
However, the process led to a strong variation of signal intensities (data not shown) and
was therefore not implemented. In order to achieve solid results, the ADA concentration
should preferably be measured in the absence of detectable drug levels [17].
3.2.4.7 Analysis of clinical samples
Samples of ten patients under a current adalimumab or infliximab treatment were ana-
lyzed (Table 3.2). As a negative control, the plasma samples of five healthy individuals
were used. Comparing the drug concentrations measured by ELISA and the process of
glucose detection, a positive correlation with a coefficient of determination of 0.877 was
observed (Figure 3.11 A). Employing TNF-α to quantify adalimumab and infliximab, it
was not possible to distinguish, which of the two drugs was present in a sample. Such a
differentiation could be implemented in a separate test. However, this was not our primary
objective, since the information about the actual treatment was known from the clinical
information.
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Figure 3.11: Analysis of patient samples(A) Correlation of drug concentrations as
determined by ELISA and measured by the competitive invertase-conjugate
iBGstar assay. Each data point represents the mean value of two
measurements. (B) The concentrations of anti-adalimumab and
anti-infliximab antibodies were determined in samples of patients under
adalimumab treatment (P3, P4, P5, P10) or infliximab treatment (P1, P2,
P6, P7, P8, P9). ADA levels above the threshold (cut-point) line were
considered as ADA positive.
According to the recommended administration schedule, adalimumab and infliximab con-
centrations were expected to be below 10 µg/ml and 70 µg/ml, respectively. For an accurate
quantification of ADAs, however, drug concentrations should be below 1 µg/ml (free drug
tolerance), which was the case only for samples P1 and P6. Nevertheless, threshold values
of 1.9 ng/ml and 1.5 ng/ml for anti-adalimumab and anti-infliximab antibodies were cal-
culated (as the upper 95th percentile of five negative control samples) and samples above
this threshold were considered to be ADA-positive. It has to be mentioned that due to
the protein-A/G oriented immobilization of drug antibodies in the used setup, only ADAs
against the fragment antigen binding (Fab) region and therefore preferably neutralizing
antibodies could be detected.
Even though patient P3 and P4 were under a current treatment with adalimumab, anti-
infliximab antibodies could be detected in both, also. The opposite was found in patient
P7; in his plasma anti-adalimumab antibodies were found despite a current treatment with
infilixmab. The information whether these patients had previously also been treated with
either adalimumab or infliximab was lacking. The development of a cross-immune-response
would be possible in principle, but seems to be unlikely and has not been reported to date.
Another possible explanation could be a very high TNF-α concentration in the plasma
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samples (> 1.2 ng/ml) resulting in a TNF bridging in the assay, which would also provide
an explanation for the relatively high ADA concentrations in P4 and P7.
3.2.4.8 Smartphone connectivity
One advantage of the presented method is the possibility of transferring the measurement
results onto a smartphone and thus to any location worldwide. A system that is directly
attachable to a smartphone was used in our experiments. Most available blood glucose
meter manufacturers offer smartphone connectivity via Bluetooth. The fact that these
devices are portable, robust, sensitive and sufficiently precise opens up a wide field of
applications, which could be adapted to the glucose measurement as demonstrated in the
applications shown here. Such a diagnostic tool can provide tests, which can be carried
out at home or somewhere remote and could reduce the patient’s need of seeing a medical
doctor. At the same time, privacy is protected. On the other hand, the data could be
transferred immediately if needed, as for serious diseases or when the results may be too
complex to be interpreted by the patient and therefore require immediate evaluation by
medical professionals.
3.2.5 Conclusion
In this study, we optimized an invertase-mediated strategy for the quantification of both
protein drugs as well as anti-drug antibodies. It can be operated with a relatively sim-
ple assay format consisting of a smartphone-attachable blood glucose meter. Optimal
invertase activity conditions allowed to generate measurable glucose concentrations within
one or three hours, respectively. An accuracy was achieved that was similar to that of
ELISA measurements. Further reduction in incubation times could be achieved with larger
amounts of magnetic beads, thus capturing more enzyme molecules, or by more sensitive
glucose meters. However, with the current setup the quantification ranges achieved meet
clinical requirements. Moreover, the option of performing this assay in combination with a
smartphone offers an additional advantage with respect to convenient patient monitoring.
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Summary
The investigations made in this thesis describe the development and optimization of minia-
turized microarray-based immunoassays, which provides sensitive and robust results in a
short amount of time to be easily applicable in a clinical setting.
In chapter 1, it was demonstrated that the microarray offers a convenient platform to
investigate the quality of antibodies. Rather than characterizing antibody by antibody
method by method in order to determine its specificity, cross-reactivity and affinity, the
microarray can effectively be used to select the most promising candidates. In our experi-
ments, 456 scFv-Fc features of unknown quality were printed on an antibody microarray.
This antibody microarray was incubated with clinical tissue samples isolated from pancre-
atic ductal adenocarcinoma and healthy pancreas, as well as recurrent and non-recurrent
bladder tumors. A significant variation in the expression of the E3 ubiquitin-protein ligase
(CHFR) and the glutamate receptor interacting protein 2 (GRIP2) was observed by more
than one scFv-Fc binding to these targets. The relevant candidates were then further
characterized with regard to cross-reactivity as well as affinity by antigen microarray and
surface plasmon resonance experiments. The characterized binders were finally used to
confirm the microarray results by immunohistochemistry analysis.
In chapter 2.1., the protein microarray method was modified to be suitable for an absolute
protein quantification. The intention of this investigation was to develop a microarray-
based protein quantification method, which could be integrated into a portable point-of-
care diagnostic system. In this respect, emphasis was placed on applicability requirements
such as convenient handling, reduced number of incubation steps and short incubation du-
rations in the first place and secondary on a tuning of the limit of detection. The prostate
specific antigen (PSA), as an established, low abundant biomarker, was used as model
protein. By the optimization of the detection antibody labeling as well as its concentra-
tion, a measurement in the range of 1 ng/ml - 1 µg/ml within 15 minutes was possible
employing a competitive quantification strategy, which required just a single incubation
step. To further improve the preciseness of measurements at low concentrations, different
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protein modification and presentation strategies were tested, yet no advantage could be
pointed out. In a simultaneous quantification experiment with PSA and TNF-α, it could
finally be demonstrated that a multiplexed quantification with more than one protein is
possible utilizing this format.
As the intactness of a protein is a prerequisite for the generation of valid results in quan-
tification experiments, a simple method to characterize the on-chip protein stability was
developed as described in chapter 2.2. For this purpose, the extrinsic fluorescent dye
thioflavin T was considered as probe to determine the degree of function loss. Four differ-
ent protein types (PSA, TNF-α, infliximab and a scFv-Fc fusion protein) were immobilized
on a microarray surface and stored at different temperatures (-20, 4, 25 and 60 ◦C). After
one, seven, thirty and ninety days the capability to be bound by detection proteins as well
as the thioflavin T-associated fluorescence were measured. Depending on the type of pro-
tein, a correlation between a decreasing protein recognition (as a result of denaturation)
and an increasing thioflavin T fluorescence (as a result of incorporation into denaturation
sites) could be pointed out. A significant negative correlation was observed for the β-sheet
rich proteins TNF-α as well as infliximab, whereas a significant positive correlation was
determined for PSA. No significant correlation was visible for the scFv-Fc fusion protein.
With this method at hand, it was possible to identify and select appropriate spotting ma-
trices as well as storage conditions to preserve the stability of each protein.
The acquired knowledge was finally used to design a microarray-based anti-drug antibody
(ADA) assays, as described in chapter 3.1. This assay combines the determination of drug
type and drug concentration, as well as the separate quantification of IgG- and IgM-ADAs.
The test performance allows a drug quantification within a range of 0.01 to 4 µg/ml (com-
petitive strategy) and an ADA quantification starting from 10 to 10,000 ng/ml (bridging
format) with a free drug tolerance of 1 µg/ml. The clinical applicability of this assay was
further demonstrated by analyzing samples from a clinical trial. This assay can be inte-
grated into a portable read-out system and thereby fulfills the initially set requirements.
An additional method, which is based on a smartphone-attachable blood glucose meter,
was developed to further optimize the existing strategy in terms of usability. The invertase-
mediated and smartphone connected method, described in chapter 3.2., allows the quan-
tification of adalimumab as well as infliximab plasma concentrations from 0.01 to 47 µg/ml
within 50 minutes. A corresponding assay, enables the quantification of ADA concentra-
tions from 1.6 to 1000 ng/ml within three hours, exhibiting a free drug tolerance of
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1 µg/ml. This smartphone connectable method offers a convenient solution to facilitate a
therapeutic drug monitoring for both, the medical professional as well as the patient.
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